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Abnormal MAPK signaling has been implicated in human malignancies. Thus, the MAPK pathways 
need to be tightly regulated. The MAPK phosphatases (MKPs), also known as dual specificity 
phosphatases (DUSPs), are a family of proteins functioning as major negative regulators of MAPKs. 
Dephosphorylation of threonine and/or tyrosine residues within the Thr-X-Tyr motif located in the 
MAPK activation loop inactivates MAPKs. Further, the MKPs/DUSPs have also been implicated in 
the development of cancers (reviewed in Low and Zhang, 2016; Kidger and Keyse, 2016).    
 
 
Figure 1. Simplified model of the MAPK signaling network (modified from reviews of Dhanasekaran 
and Johnson, 2007; Johnson, 2011; Tomida, 2015). The molecules and factors marked in the 







































c-Jun, a member of the AP-1 transcription factor family, is involved in numerous cell activities 
such as proliferation, differentiation, tissue morphogenesis, tumorigenesis, and apoptosis. c-
Jun is a basic leucine zipper (bZIP) transcription factor that can form homodimers and 
heterodimers with other AP-1 family members. As a dimer, it is able to bind to DNA and 
regulate transcription of different genes. Numerous extracellular stimuli, such as ultraviolet 
(UV) radiation, and cellular stimuli, such as reactive oxygen species (ROS), induce signaling 
cascades leading to phosphorylation and activation of c-Jun. The main kinase phosphorylating 
c-Jun is c-Jun N-terminal kinase (JNK). c-Jun is constitutively activated in many human 
cancers, including melanoma, breast, pancreatic, and colorectal cancers, and transformed cell 
lines, like Ha-ras transformed fibroblasts. Thus, better knowledge of the activation of c-Jun 
and the genes it regulates in cell transformation is needed in the fight against cancer. 
The aim of this study was to clarify the role of c-Jun in cell transformation by using 
fibrosarcoma and melanoma cells as models. In the first part of the study, the significance of 
phosphorylation and activation of c-Jun in S-adenosylmethionine decarboxylase (AdoMetDC)-
, ornithine decarboxylase (ODC)-, and Ha-ras oncogene-transformed mouse fibroblasts 
(Amdc, Odc, and E4 cells, respectively) was examined by exploiting transactivation domain 
deletion mutant of c-Jun (TAM67) and phosphorylation-deficient c-Jun mutants. Further, the 
upstream kinases of c-Jun were evaluated by using dominant negative mutants of SEK1 
(MKK4) and JNK1 as well as JNK inhibitors.  The transformed morphology of the cells was 
reversed with differing efficacies when transfected with these mutants, most effectively when 
using TAM67.  Due to the highest potency of TAM67, Amdc, Odc, and E4 cells carrying a 
tetracycline-inducible expression system of TAM67 were then generated (Amdc-, Odc-, and 
E4- pLRT-TAM67 cell lines). These inducible cell lines provide good, reversibly regulatable 
models to identify the mechanisms of c-Jun-related transformation. Indeed, expression of 
TAM67 inhibited cell growth in soft agar and three-dimensional (3D) Matrigel matrix, and, 
most importantly, tumor formation in nude mice.                                                                                                                                                                                                                                                                                                      
In the second part of the study, the transformation-relevant genes regulated by c-Jun in Amdc, 
Odc, and E4 cells were identified by utilizing the above-mentioned cell lines (Amdc-, Odc-, 
and E4-pLRT-TAM67). After TAM67 induction, the differentially expressed genes in the 
morphologically normalized cells compared with the transformed cells were identified by 




including those of integrins 6 and 7 (Itg6 and Itg7), which were upregulated in 
transformed cells, and lysyl oxidase (Lox), which was downregulated. In addition to Lox, also 
Lox-like-1 and 3 were found to be downregulated in Odc and E4 cells by Affymetrix’s 
microarray and RT-PCR analyses.   
In the third and fourth parts of the study, the functional roles of the up- and downregulated 
genes were examined. Itg6 was found to pair mainly with Itg1 to form integrin 61 
heterodimer, and function-blocking antibodies against Itg6 or Itg1 inhibited the binding of 
Amdc cells to laminin and cell invasion in 3D Matrigel. Importantly, similar results were seen 
with human HT-1080 fibrosarcoma cells. Further, downregulated Lox (pro-LOX) was 
observed to be involved in the invasion of Odc cells. In addition to fibrosarcoma cells, the 
expressions of LOX family members were also examined in different human melanoma cell 
lines, where they were variably expressed. LOXL2 and LOXL3 were upregulated in nearly all 
melanoma cell lines studied.  Upregulated LOX family members and their activities were found 
to be associated with invasion in melanoma cells, especially when co-cultured with fibroblasts 
in 3D Matrigel. 
In conclusion, we have demonstrated that the transformed phenotype of ODC-, AdoMetDC-, 
and Ras-transformed mouse fibroblasts is reversibly regulatable by dominant negative mutants 
of c-Jun and identified Itg6 and Lox as transformation-relevant target genes of c-Jun. Inactive 
pro-LOX is suggested to act as a tumor suppressor in these cells. In human melanoma cells, in 
turn, active LOX and LOXL2 were identified as molecules promoting invasive growth and 
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Cancer was estimated to cause 9.6 million deaths worldwide in 2018 (World Health 
Organization, 2018), and it is the second most common reason for deaths in Finland, causing 
23% of all deaths in 2017 (Statistics Finland, 2017). Cancer incidence is rising because people 
are living longer. Cancer development is a multistep process. Epigenetic abnormalities and 
genetic alterations may result in inappropriate gene regulation, leading to cancer development. 
Tumor growth and progression have been proposed to depend on several acquired capabilities 
designated as hallmarks of cancer: sustained proliferative signaling, evasion of growth 
suppressors, replicative immortality, invasion and metastasis, angiogenesis, and resistance of 
cell death (reviewed in Hanahan and Weinberg, 2000). In addition to these six core hallmarks 
of cancer, two enabling characteristics and two emerging hallmarks were added to the list 
characterizing tumor cells: genomic instability and mutability and tumor-promoting 
inflammation, and capability to modify cellular metabolism to support neoplastic proliferation 
and avoidance of immune destruction (reviewed in Hanahan and Weinberg, 2011). Different 
tumor types acquire these capabilities via distinct mechanisms and at various times during the 
multistep tumorigenesis. Furthermore, progression of the cancer is associated with a complex 
interplay between the tumor cells and surrounding non-neoplastic cells and the extracellular 
matrix. 
Tumorigenesis can be seen as a dysfunction of signal transduction networks that regulate 
molecular communications and cellular processes (reviewed in Sever and Brugge, 2015). The 
alterations that allow cells to overproliferate and escape the controlling mechanisms of survival 
and migration may map to a multitude of signaling pathways. One of the affected pathways is 
the mitogen-activated protein kinase (MAPK) cascade, which is critical in many processes 
related to malignancy. The mammalian MAPK family consists of extracellular signal-regulated 
kinase (ERK), p38, and c-Jun NH2-terminal kinase (JNK) (reviewed in Kyriakis and Avruch, 
2012). In our study, we investigated especially the JNK pathway, which leads to activation of 
the transcription factor c-Jun. The main focus was c-Jun and the genes regulated by c-Jun in 
the malignant cell transformation. c-Jun is one of the members of the activator protein-1 (AP-
1) transcription factor complex.  It is involved in many cellular processes such as proliferation, 




Meng and Xia, 2011). In line with this, activated c-Jun plays a role in carcinogenesis and cancer 
progression (reviewed in Weiss and Bohmann, 2004).  
To study the role of c-Jun in cell transformation, we used ornithine decarboxylase (ODC)-
transformed mouse fibroblast cells (Auvinen et al., 1992) and S-adenosylmethionine 
decarboxylase (AdoMetDC)-transformed fibroblasts. ODC and AdoMetDC are the key 
regulatory enzymes in the biosynthesis of polyamines (reviewed in Miller-Fleming et al., 
2015). The polyamines putrescine, spermidine, and spermine are essential for cell proliferation 
and are involved in cell transformation. In addition, Ha-rasval12-transformed fibroblasts were 
used in the studies. RAS protein family members (HRAS, NRAS, and KRAS) belong to small 
GTPases, which are attached to the cell membrane and transmit signals within cells. They are 





REVIEW OF LITERATURE 
1. MAPK SIGNAL TRANSDUCTION PATHWAY 
Cells need to respond to a diverse, complex, and changing set of signals. Changes in protein 
expression level, localization, activity, and protein-protein interactions are important in signal 
transduction, enabling cells to react highly specifically to circumstantial changes and vary 
effectively the response (reviewed in Lee and Yaffe, 2016). Extracellular signals activate the 
cell surface receptors, e.g. different integrins (reviewed in Rathinam and Alahari, 2010), which 
transduce signals across the plasma membrane into the cytoplasm. A complex network of 
signal transducing proteins in the cytoplasm then processes the signals and transduces them 
into the nucleus, where activated transcription factors regulate the expression of different 
genes, which in turn are responsible for the different cellular responses. There are numerous 
different pathways mediating signals in the cells, including the MAPK pathway (reviewed in 
Weston and Davis, 2007). Transmission signals via the MAPK pathway are usually initiated 
by activation of small G-proteins, like RAS, followed by activation of a sequential set of protein 
kinases (reviewed in Shaul and Seger, 2007). In cancer pathogenesis, these signaling cascades 
do not function properly, leading to abnormal cell proliferation and the potential to invade other 
parts of the body. 
1.1  MAPKS  
MAPKs are activated by extracellular and intracellular stimuli involving peptide growth 
factors, cytokines, hormones, and cellular stress. MAPKs include JNK, ERK, and high 
osmolarity glycerol response kinase (p38), which are regulated spatio-temporally within cells 
(reviewed in Atay and Skotheim, 2017; Tomida, 2015). All of these signaling pathways consist 
of at least three components (see Figure 1): a MAPK kinase kinase (MAPKKK), a MAPK 
kinase (MAPKK) and a MAPK, where MAPKKKs phosphorylate and activate MAPKKs, and 
MAPKKs in turn phosphorylate and activate MAPKs (reviewed in Dhanasekaran and Johnson, 
2007). There are at least 20 MAPKKKs, 7 MAPKKs and 11 MAPKs. Activated MAPKs 
generally detach from the scaffold and translocate to the nucleus. MAPKs have many different 
substrates, including predominantly transcription factors, which regulate genes involved in cell 
proliferation, differentiation, survival, and death. Different MAPKs can activate an overlapping 
set of transcription factors.  
Supervisor   Docent Erkki Hölttä, MD, PhD 
  Faculty of Medicine 
University of Helsinki 
 
 
Thesis committee Professor Antti Vaheri, MD, PhD 
Faculty of Medicine 
University of Helsinki 
 
 
Professor Jim Schröder, PhD 
Faculty of Biological and Environmental Sciences 
University of Helsinki 
 
 
Reviewers   Docent Jarmo Käpylä, PhD 
Department of Biochemistry 
University of Turku 
 
 
  Docent Päivi Koskinen, PhD 
Department of Biology 
University of Turku 
 
 
Opponent  Docent Liisa Nissinen, PhD 
Department of Dermatology and Venereology 
University of Turku 
 
 
Custos  Professor Juha Partanen, PhD 
Faculty of Biological and Environmental Sciences  







The Faculty of Biological and Environmental Sciences uses the Urkund system (plagiarism 
recognition) to examine all doctoral dissertations. 
 
 
ISBN 978-951-51-6658-6 (paperback) 







Abnormal MAPK signaling has been implicated in human malignancies. Thus, the MAPK pathways 
need to be tightly regulated. The MAPK phosphatases (MKPs), also known as dual specificity 
phosphatases (DUSPs), are a family of proteins functioning as major negative regulators of MAPKs. 
Dephosphorylation of threonine and/or tyrosine residues within the Thr-X-Tyr motif located in the 
MAPK activation loop inactivates MAPKs. Further, the MKPs/DUSPs have also been implicated in 
the development of cancers (reviewed in Low and Zhang, 2016; Kidger and Keyse, 2016).    
 
 
Figure 1. Simplified model of the MAPK signaling network (modified from reviews of Dhanasekaran 
and Johnson, 2007; Johnson, 2011; Tomida, 2015). The molecules and factors marked in the 







JNKs are known as stress-activated protein kinases (SAPKs), and they belong to the MAPK 
superfamily. Three JNK genes, Jnk1, Jnk2, and Jnk3, are known, but due to alternative splicing 
there are up to 10 different protein products. While jnk1 and jnk2 genes are expressed 
ubiquitously in all tissues, jnk3 expression is restricted primarily to the brain, heart, and testes 
(reviewed in Weston and Davis, 2007; Bogoyevitch and Kobe, 2006; Davis, 2000).  
The JNK family members regulate a diverse set of cellular processes, including cell 
proliferation, differentiation, migration, inflammation, and apoptosis. JNKs are activated by 
extracellular stimuli caused by stress (UV irradiation, hyperosmolarity, heat shock), but also 
by intracellular stimuli, such as endoplasmic reticulum (ER) stress, which is caused by the 
disruption of protein processing and folding within the ER (Win et al., 2014). Furthermore, 
several growth factors, proinflammatory cytokines (TNF-, IL-1), and Toll-like receptor 
ligands from invading pathogens lead to JNK activation.     
The JNK pathway involves the activation of various small G proteins and the engagement of 
adaptor proteins, followed by activation of a protein kinase cascade, comprising various 
members of the MAPKKK family (reviewed in Sehgal and Ram, 2013). Finally, JNK is 
activated by dual phosphorylation performed by the MAPK kinases MKK4 and MKK7 on 
specific threonine and tyrosine residues in a typical Thr-X-Tyr motif. Activated JNKs can then 
phosphorylate their substrates in different locations (Tournier et al., 1997; Derijard et al., 
1995). 
The number of known JNK substrates is close to 100 (reviewed in Bogoyevitch and Kobe, 
2006; Zeke et al., 2016). They are predominantly nuclear, such as transcription factors and 
hormone receptors, but also cytoplasmic proteins, cell membrane receptors, and mitochondrial 
protein substrates exist. The nuclear translocation of JNKs is a nuclear translocation sequence 
(NTS)-independent process, mediated by distinct β-like importins (reviewed in Flores et al., 
2019). The proto-oncogenic transcription factor c-Jun was the first JNK substrate to be known, 
thus giving JNKs their name c-Jun N-terminal kinases. JNKs can phosphorylate and activate 
c-Jun on serines 63 and 73 as the major phosphorylation sites, but also on threonines 91 and 
93. In addition to c-Jun, JNKs can phosphorylate and activate other AP-1 family members such 
as JunB, JunD, and activating transcription factor 2 (ATF2) (reviewed in Bogoyevitch and 




JNK signaling has been linked to several pathological conditions such as neurodegenerative 
diseases, autoimmune diseases, diabetes, asthma, cardiac hypertrophy, and cancer (reviewed 
in Sabapathy, 2012; Kumar et al., 2015; Cui et al., 2007; Koch et al., 2015). JNKs are thought 
to have an oncosuppressive role in cancer by mediating apoptosis, but many studies have also 
implicated them, especially JNK1, in malignant transformation and tumor growth (reviewed in 
Liu and Lin, 2005; Gkouveris and Nikitakis, 2017; Tournier, 2013; Das et al., 2011). However, 
also evidence for a predominant role for JNK2 in Ras-induced transformation has been 
presented (Nielsen et al., 2007). Moreover, JNKs have been shown to be involved in all steps 
of the metastatic cascade, starting from the promotion of epithelial-to-mesenchymal transition 
in tumor cells to promotion of proliferation of seeded tumor cells and their surveillance at the 
metastatic site (reviewed in Ebelt et al., 2013). The diversity of JNK upstream and downstream 
signaling may lead to contradictory functions of JNK in cancer. In addition, JNK1 and JNK2 
have been shown to have discrete or even opposite functions, e.g. JNK1 phosphorylates c-Jun, 
leading to cell proliferation, while JNK2 reduces c-Jun stability, leading to decreased 
proliferation (Sabapathy et al., 2004). 
Improved understanding of the complexity of JNK signaling can potentially lead to 
development of novel therapeutic strategies for cancer and other diseases (reviewed in Cui et 
al., 2007; Kumar et al., 2015; Koch et al., 2015; Xu, and Hu, 2020). For example, anti-cancer 
compounds that induce severe ROS accumulation, causing activation of JNK-mitochondrial 
and ER stress pathways and leading to apoptosis of cancer cells, have potential as clinical 
therapeutic agents (Zou et al., 2015; Che et al., 2017). 
1.1.2 ERKs 
ERKs, other members of the MAPK superfamily, include ERK1 and ERK2. They are 
ubiquitous regulators of multiple cellular processes, including proliferation, differentiation, 
development, cell survival, transformation, and, under some conditions, apoptosis. Similarly 
to JNKs, also ERKs have been found to be involved in both oncogenesis and tumor suppression 
(reviewed in Deschenes-Simard et al., 2014). Ras/Raf/MEK/ERK pathway has also been 
shown to be activated in many cancer types, such as melanoma and colorectal cancer, and ERK 
inhibitors and other therapeutic agents have been developed (reviewed in McCubrey et al., 
2007; Burotto et al., 2014; Savoia et al., 2019; Degirmenci et al., 2020).  
ERKs are activated by growth factors and mitogens through the Ras/Raf/MEK/ERK signaling 
cascade. Ras is a small GTPase, which is mutated in up to 30% of human cancers. Protein 




recruited by Ras. Raf dimers then phosphorylate the dual-specificity kinases MEK 
(MAPK/ERK kinase), which in turn activate ERK through dual phosphorylation of its 
regulatory tyrosine and threonine residues (reviewed in Dorard et al., 2017). Activated ERKs 
can phosphorylate large numbers of substrates, which are localized in the cytoplasm or nucleus. 
These substrates include signal transduction protein kinases like BRAF, transcription factors 
such as Elk1, Ets1/2, and MYC, and many of the AP-1 family members like c-Jun, JUNB, 
JUND, FOS, and ATF2 (http://sys-bio.net/erk_targets/targets_all.html; reviewed in Unal et al., 
2017). 
1.1.3 p38 
p38 MAPK is known as stress-activated MAPK, being responsive to cellular stress and 
cytokines. Four genes encoding p38 MAPKs are MAPK14, encoding p38, MAPK11, 
encoding p38, MAPK12, encoding p38, and MAPK13, encoding p38. p38 is highly 
abundant in most cell types, the others having more restricted expression. A specific inhibitor 
is available for p38, the thus far best characterized member of the p38 MAPK family 
(reviewed in Igea and Nebreda, 2015). In addition to having different tissue-specific expression 
patterns, the p38 family members differ by their regulation of upstream stimuli, selectivity for 
upstream regulatory kinases and phosphatases, sensitivity to chemical inhibitors and different 
downstream targets (reviewed in Roux and Blenis, 2004).  
Upstream kinases MKK3 and MKK6, and sometimes MKK4, activate p38 MAPK by dual 
phosphorylation (Derijard et al., 1995), and activated p38 MAPKs in turn are known to regulate 
by phosphorylation more than 100 proteins. Half of these are transcription factors, including 
members of AP-1 family: ATF2, c-Fos, c-Jun, and MafA (Trempolec et al., 2013). The rest of 
the substrates comprise protein kinases and phosphatases, cell cycle and apoptosis regulators, 
growth factor receptors, and cytoskeletal proteins (Trempolec et al., 2013). 
p38 signaling plays an important role in immune response and regulation of cell survival and 
differentiation. Furthermore, it is involved in different human diseases such as inflammation, 
cardiovascular dysfunction, Alzheimer’s disease, and cancer (reviewed in Cuenda and 
Rousseau, 2007). Like other MAP kinases, p38 has also both tumor-suppressive and oncogenic 
functions (reviewed in Hui et al., 2007; Igea and Nebreda, 2015; Bulavin and Fornace, 2004). 
The role of p38 MAPK signaling in cancer is shown to be cell- and tumor-type dependent 
(reviewed in Gupta and Nebreda, 2015). For instance, p38/ATF2 expression plays a crucial 




p38 activity accelerates proliferation and migration of breast cancer cells (Huth et al., 2017). 
However, p38 was found to be significantly less active in human hepatocellular carcinoma 
tissue than in adjacent non-neoplastic tissue (Iyoda et al., 2003). Interestingly, it has also been 
shown that p38 has a dual function in colon cancer: suppressing inflammation-associated 
epithelial damage and tumorigenesis, but promoting proliferation and survival of tumor cells 
(Gupta et al., 2014). 
2. AP-1 TRANSCRIPTION FACTOR 
AP-1 is a dimeric transcription factor consisting of members of the JUN (c-Jun, JUNB, and 
JUND), FOS (c-FOS, FOSB, and FOS-related antigens Fra-1 and Fra-2), ATF (ATF1, ATF2, 
liver regeneration factor 1 LRF1/ATF3, B-ATF, Jun dimerization proteins JDP1 and JDP2, 
cAMP-response element-binding protein CREB, cAMP-response element modulator CREM) 
and musculo-aponeurotic fibrosarcoma MAF (c-Maf, MafB, MafA, MafG/F/K, and neural 
retina-specific leucine zipper protein Nrl) protein subfamilies. JUN and FOS of these 
subfamilies constitute the major AP-1 proteins. Common to all of these proteins is the leucine-
zipper domain, which is essential for dimerization, and a basic domain required for DNA 
binding. Dimerization brings together the basic regions, which then interact with specific 
sequences of DNA. In addition, MAF transcription factors have been thought to belong to the 
AP-1 superfamily because they share structural similarities like the basic leucine-zipper (bZIP) 
regions. Their functions are, however, distinctly diversified when compared with the other AP-
1 proteins (reviewed in Katsuoka and Yamamoto, 2016).  
Due to the multiple dimerization partners, AP-1 proteins can form many combinations of 
homo- and heterodimers, which in turn determine the gene to be regulated (Bakiri et al., 2002; 
reviewed in Bejjani et al., 2019). They regulate genes involved in many cellular processes such 
as cell proliferation, inflammation, differentiation, apoptosis, angiogenesis, migration, and 
invasion. AP-1 proteins are mainly considered to be oncogenic, but some of them have been 
shown to have tumor suppressor activity as well. This may depend on the antagonistic activity 
of different JUN proteins and also the type, stage, and genetic background of tumors (Table 1) 







Table 1. Roles of Jun family members in cancer are context-dependent (reviewed in Shaulian, 
2010; Eferl and Wagner, 2003). 
JUN FAMILY 
MEMBER 




enhances cell proliferation, migration, invasion, and 





migration, invasion, metastasis 
 
inhibits cellular proliferation and transformation 
JunD Oncogene 
Tumor suppressor 
induces proliferation, inhibits apoptosis 




The cellular Jun (c-Jun) is a dominant component of AP-1 complexes in many cell lines (Angel, 
Allegretto et al., 1988; Bos et al., 1988; reviewed in Bohmann et al., 1987). Jun was first 
characterized as a viral oncoprotein, v-Jun, derived from avian sarcoma virus 17 (ASV17), 
which causes progressive fibrosarcoma in chicken and transforms chick embryo fibroblasts 
(Maki et al., 1987). v-Jun differs from c-Jun by a 27-amino acid deletion near the N-terminus 
(delta deletion), where the binding domain of JNK is situated, and three amino acid 
substitutions in the C-terminal half (Nishimura and Vogt, 1988). One of these amino acid 
substitutions of v-Jun is serine-243, which is mutated to phenylalanine. Because of this 
substitution, glycogen synthase kinase 3 (GSK3) is not able to mark it by phosphorylation, 
which allows v-Jun to escape recognition and destruction of Fbw7 (F-box and WD repeat 
domain-containing 7) ubiquitin ligase complex (Wei et al., 2005). However, c-Jun, as a single 
oncoprotein, is also able to transform rat fibroblast cell line Rat1a on its own, and in 
cooperation with activated ras gene, it can transform primary rat embryo cells (Schutte et al., 
1989). In addition, c-Jun is able to act in synergy with oncogenic Ras to transform normal 
epidermal cells into malignant ones (Jin, J. Y. et al., 2011).  
2.1.1 Structure of c-Jun 
The human JUN gene is located on chromosome 1 at region p31-32 (Haluska et al., 1988; 
Hattori et al., 1988), whereas murine Jun is on chromosome 4, subregion C5-C7 (Mattei et al., 
1990). Cloning of the c-jun gene surprisingly showed it to be intronless and to have an atypical 




gene contains a c-Jun/AP-1 binding site, so c-Jun mediates positive autoregulation of its own 
gene product (Angel, Hattori et al., 1988).  
c-Jun is a 39 kDa nuclear phosphoprotein comprising an N-terminal transcriptional activation 
domain and a C-terminal bZIP domain, which in turn consists of a basic DNA binding domain, 
followed by an -helical leucine zipper dimerization domain (Figure 2) (reviewed in Vogt and 
Morgan, 1990). The locations of functional domains and phosphorylation sites in c-Jun are 
shown in Figure 2. In the proximity of the N-terminus of c-Jun is the delta domain, to which 
the MAP kinase JNK binds. JNK then activates c-Jun by phosphorylating its transactivation 
domain, on serines 63/73 (S63/73), which are the major sites of phosphorylation. Under some 
circumstances, also threonines 91/93 (T91/93) can be phosphorylated (reviewed in Dunn et al., 
2002). Negative regulatory phosphorylation sites of c-Jun are located proximal to the DNA-
binding domain on threonine 239 and serines 243 and 249 in the C-terminus. They are 
phosphorylated by GSK3 (Boyle et al., 1991; Morton et al., 2003). Various stimuli can decrease 
the C-terminal domain phosphorylation, thereby increasing the DNA binding affinities of c-
Jun. 
 
Figure 2. Structure of c-Jun. JNK binding site in the delta domain and JNK phosphorylation 
sites in the transactivation domain are located in the N-terminus. The C-terminus contains a 
basic region for DNA binding, leucine zipper for dimerization, and phosphorylation sites for 
negative regulation. 
c-Jun can dimerize with different partners, thus recognizing different sequence elements in the 
promoters and enhancers of target genes (reviewed in Bejjani et al., 2019).  c-Jun, which forms 
homodimers or dimerizes with JunB, JunD, c-Fos, FosB, FRA1, or FRA2, prefers binding to 




induced by the tumor promoter 12-O-tetradecanoyl-phorbol 13-acetate (TPA). Heterodimers 
with c-Fos are more stable than c-Jun homodimers and have a higher affinity for the DNA 
target sequence. When c-Jun dimerizes with different ATF proteins, it in turn preferentially 
binds to cAMP-response element (CRE) 5’-TGACGTCA-3’ (reviewed in Eferl and Wagner, 
2003). Interestingly, it has been found that c-Jun/c-Fos heterodimers can bind methylated 
promoters when the gene is repressed and can reverse the epigenetic silencing and induce 
expression of that gene (Gustems et al., 2014).  
2.1.2 Activation and regulation of c-Jun 
c-JUN is an immediate early gene activated by proinflammatory cytokines, genotoxic stress, 
ROS, UV radiation, hormones, and growth factors. The activity of c-Jun protein is stimulated 
by signaling pathways through MAPKs: JNK, ERK, and p38 families. c-Jun N-terminal 
phosphorylation at serines 63 and 73 and threonine 91 or 93 or both in its transactivation 
domain increases transcription of c-Jun target genes, including the c-jun gene itself. Indeed, c-
Jun transcription is directly stimulated by its own gene, creating a positive regulatory loop 
(Angel, Hattori et al., 1988). In many human cancers, overexpression of c-Jun is the result of 
upstream oncogene activation, but also amplifications of the c-Jun locus have been observed 
in undifferentiated and aggressive human sarcomas (Mariani et al., 2007).  
c-Jun activity can be regulated by different mechanisms, including transcription, post-
translational modification, dimerization of partners, and interaction with accessory proteins. 
Depending on the regulation mechanisms, a given AP-1 factor can regulate a specific target 
gene positively or negatively. In the absence of JNK signaling, a repressor complex containing 
histone deacetylase 3 (HDAC3) interacts with the N-terminal region of c-Jun and inhibits it. 
Phosphorylation of c-Jun by JNK causes dissociation of the HDAC3 complex and relieves 
suppression of the transcriptional activity of c-Jun (Weiss et al., 2003).  
c-Jun can further be regulated by ubiquitylation and proteasomal degradation. In the G1/S 
transition, c-Jun rapidly accumulates when quiescent cells are stimulated to proceed in the cell 
cycle. If the cells return to quiescence, c-Jun is again cleared by ubiquitin-mediated proteolysis. 
Thus far, three ubiquitin ligases have been reported to trigger ubiquitylation and degradation 
of c-Jun. One of them is Itch, whose E3 ligase activity needs to be activated by JNKs (Gao, M. 
et al., 2004). The second ligase is the ubiquiting E3 ligase, Fbw7, which mediates degradation 
depending on C-terminal phosphorylation of c-Jun by GSK3(Wei et al., 2005)Previous 
studies have also shown that adaptor protein Rack1 can enhance oncogenic c-Jun stability by 




c-Jun is then phosphorylated by JNKs or other kinases, the Rack1-Fbw7 complex is released 
from c-Jun, leading to protection of c-Jun from degradation (Zhang, J. et al., 2012). The third 
ubiquitin ligase is the E3 ubiquitin ligase constitutive photomorphogenesis protein 1 (Cop1), 
which functions as a tumor suppressor, antagonizing c-Jun oncogenic activity. Thus the loss of 
Cop1 may be one mechanism leading to c-Jun upregulation in human cancers (Migliorini et 
al., 2011).  
2.1.3 Putative target genes of c-Jun and their functions in tumorigenesis 
Oncogene activation is often an early step in neoplastic progression. Aberrant activation of c-
Jun is known to be critical in regulation of a complex program of gene expressions involved in 
the different aspects of tumorigenesis. Figure 3 shows some of the putative genes up- and 
downregulated by c-Jun during tumorigenesis (Sioletic et al., 2014; reviewed in Eferl and 
Wagner, 2003). However, previously published data of the genes directly regulated by c-Jun 
in cancer cells did not include, for example, the genes cyclin D1 and p53 (Schummer et al., 
2016). This may indicate that some earlier published cancer-related and putative c-Jun 
regulated genes are probably regulated indirectly by c-Jun.    
There are three steps in carcinogenesis: initiation, promotion, and progression, the latter two of 
which require activated c-Jun. Increased expression and constitutive activation of c-Jun have 
been detected in multiple human cancers, one of them being malignant melanoma, which is the 
most aggressive skin tumor (reviewed in Kappelmann et al., 2014). Recently, 44 genes were 
reported to be directly regulated by c-Jun in cancer cell lines, and six of them were analyzed in 
more detail in melanoma cells (Schummer et al., 2016). Furthermore, overexpression of c-Jun 
is detectable in human pancreatic (Tessari et al., 1999), breast (Gee et al., 2000), colorectal 
(reviewed in Ashida et al., 2005), and squamous cell carcinoma (Jin, J. Y. et al., 2011) as well 








Figure 3. Schematic diagram of putative genes up- or downregulated directly or indirectly by 
c-Jun during tumorigenesis (modified from Sioletic et al., 2014; Zhang, G. et al., 2006; 
reviewed in Eferl and Wagner, 2003). EGFR: epidermal growth factor receptor; FASL: FAS 
ligand; GM-CSF: granulocyte-macrophage colony-stimulating factor; HB-EGF: heparin-
binding epidermal growth factor; MMP: matrix metalloproteinase; ENPP2: ectonucleotide 
pyrophosphatase/phosphodiesterase 2 (autotaxin).   
 
2.1.3.1 c-Jun in cell proliferation  
Thus far, most of the aberrantly directly or indirectly regulated target genes of c-Jun have been 
found to be involved in cell proliferation. c-Jun is indeed one of the regulators of the G1/S 
transition in the cell cycle. The genes that are positive regulators of cell cycle progression, such 
as cyclin D1 and cyclin A, are induced by the activated c-Jun-containing AP-1 complex (Bakiri 
et al., 2000; Katabami et al., 2005). Hennigan and Stambrook (2001) have expressed 
transactivation domain deletion mutant of c-Jun, TAM67, in human fibrosarcoma cells 
(HT1080), which led to inactivation of cyclin D1:cdk4/6 and cyclin E:cdk2 complexes and 
arrested cells in G1, showing c-Jun to upregulate cyclin D1 and cyclin E in fibrosarcoma cells. 
In the normally regulated cell cycle, c-Jun and junB phosphorylation states and quantities have 
been shown to vary at the M-G1 transition (Bakiri et al., 2000). Phosphorylation of JunB leads 
to lower JunB protein levels in mitotic and early G1 cells, while N-terminal phosphorylation of 




cyclin D1 promoter, which is needed for progression through the G1 phase of the cell cycle. 
Further, the tumor suppressor  BLU (-catenin in lung cancer) has been reported to inhibit 
phosphorylation of c-Jun and to lead to downregulation of cyclin D1 promoter activity and cell 
cycle arrest at G1 phase (Zhang X Ph et al., 2012).  
Negative regulators of cell cycle progression, such as tumor suppressor p53 and its target gene 
CDK inhibitor p21 and the cyclin-dependent kinase inhibitor INK4A, are, in turn, repressed by 
c-Jun (Schreiber et al., 1999; reviewed in Kollmann et al., 2011). In line with this, Maritz et al. 
(2011) found that in cervical cancer, TAM67 inhibits cell proliferation and increases the 
expression of cell cycle regulatory protein p21, which appeared to be the key player in growth 
arrest induced by TAM67. 
2.1.3.2 c-Jun and apoptosis 
Apoptosis is a process of programmed cell death to eliminate unwanted cells from the 
organism. c-Jun has been shown to either inhibit (Katiyar et al., 2010) or induce (Bossy-Wetzel 
et al., 1997) cellular apoptosis depending on its expression level, the cell type, and the context 
of other regulatory influences. Previously, Ferraris et al. (2012) showed that under stress, the 
nucleolar apoptosis-antagonizing transcription factor (AATF) is required as a co-factor for c-
Jun-mediated apoptosis. In liver tumors, c-Jun prevents apoptosis by antagonizing the activity 
of p53 (Eferl et al., 2003). 
2.1.3.3 c-Jun and migration 
Autotaxin (ENPP2), a secreted nucleotide pyrophosphatase/phosphodiesterase (NPP), first 
identified as a motility-stimulating factor in melanoma cells (Stracke et al., 1992), has been 
identified as a special target of v-Jun in v-Jun-transformed chicken embryo fibroblasts (Black 
et al., 2004). Also, autotaxin/ENPP2 has been found to be a target of c-Jun in human soft tissue 
sarcomas (Sioletic et al., 2014). Based on these findings, current research is focused on 
autotaxin as a possible pharmacological target in melanoma (reviewed in Jankowski, 2011).  
2.1.3.4 c-Jun and invasion 
Cellular invasion takes place in normal biological processes such as development, immune 
response, and wound healing. In normal cells, invasion is tightly regulated, but overexpressed 
growth factors and constitutively activated oncogenes are able to directly induce cell motility 
and invasion. In tumorigenic invasion, the cells gain the ability to move through the basement 
membrane and three-dimensional space within host tissues. Finally, in metastasis the tumor 
cells gain access to vascular or lymphatic systems and spread to distant sites to grow. 




AP-1 activation regulates invasion in metastatic human tumors by activating or repressing the 
genes involved in invasion (reviewed in Ozanne et al., 2007; Ozanne et al., 2000). For example, 
endogenous c-Jun can enhance mammary epithelial tumor cellular migration and invasion (Jiao 
et al., 2010). Transforming growth factor beta (TGF-a multifunctional cytokine, has been 
shown to play a bifunctional role in tumorigenesis and cellular migration. Janowski et al. 
(2011) have shown that TGF--induced calcium signaling and migration are dependent on c-
Jun. In their study, the authors used floxed c-Jun transgenic mice and compared the c-jun wild 
type with the conditional c-jun knockout cells. According to their results, TGF- induced cell 
migration, accompanied by a rise in nuclear calcium, which required an intact c-jun/IP3 
signaling pathway. 
AP-1 has further been implicated in the regulation of genes involved in matrix remodeling. 
Degradation of the extracellular matrix (ECM) by matrix metalloproteinases (MMPs) is a 
crucial step in tumor invasion and metastasis (reviewed in Westermarck and Kahari, 1999). For 
example, the promoter of collagenase/MMP-1 gene contains an AP-1 binding site. The signals 
leading to MMP expression have been found to be regulated by EGFR through MAPK and AP-
1 pathways (Kajanne et al., 2007).  Phosphorylated c-Jun and Fra-1 have further been shown 
to bind to the AP-1 binding site of the MMP-1 promoter in 143B osteosarcoma cells, leading 
to MMP-1 expression and cell invasion (Kimura et al., 2011). Furthermore, also the type IV 
collagenase, MMP-9, contains an AP-1 binding site in its promoter and c-Jun is one of its 
regulators. Park et al. (2014) have found that the small leucine zipper protein (sLZIP) induces 
c-Jun and MMP-9 expression in cervical cancer cells, resulting in cell migration and invasion. 
sLZIP belongs to basic leucine zipper transcription factors of the CRE/ATF gene family. In 
addition, c-Jun is also involved in regulation of other proteinases, e.g. cathepsin L, degrading 
the extracellular matrix (Ravanko et al., 2004). Besides invasion and metastasis, MMPs are 
also capable of promoting angiogenesis. 
2.1.3.5 c-Jun and angiogenesis 
The activation of c-Jun is also linked to angiogenesis. Angiogenesis is a complex and multilevel 
process where new blood vessels form from pre-existing vasculature. Under normal conditions, 
angiogenesis takes place during wound healing and reproduction. Interestingly, Zhang et al. 
(2004) used DNAzyme targeting c-Jun mRNA (Dz13) and showed that the human endothelial 
cells could no longer form new blood vessels in vitro or in vivo. Indeed, endothelial cell 
proliferation, migration, chemoinvasion, and tubule formation was blocked by Dz13. 




is known to be involved in the process of angiogenesis. Moreover, previous studies have 
identified proliferin, a placental hormone, as a c-Jun-regulated angiogenic factor in 
fibrosarcoma cell lines (Toft et al., 2001).  In breast cancer, activated c-Jun has been shown to 
be predominantly expressed at the invasive front and to be associated with angiogenesis 
(Vleugel et al., 2006).  
2.1.3.6 Other putative c-Jun target genes in tumorigenesis 
c-Jun has also been reported to regulate the transcription of phosphoinositide-dependent kinase 
1 (PDK1), which is a kinase required for the activation of other kinases such as Akt and protein 
kinase C (PKC) (Lopez-Bergami et al., 2010). Akt and PKC signal transduction pathways, in 
turn, are important in tumor development and progression in many tumor types.   
Dhar et al. (2004) identified by microarray analysis six AP-1-regulated genes that are critical 
in epithelial tumor promotion. These genes were TPA-inducible and suppressed by TAM67, 
three of them being transcription factors: c-Jun, high-mobility group A1 (HMGA1), and 
transcription factor IIb (TFIIb9), and the other three a translation initiation factor (eIF4a), an 
early regulator of the NF-kB signaling pathway (IkBa), and an expressed sequence tag (EST) 
with coding similarities to a mouse caveolar protein. Notably, HMGA1 binds to the AT-rich 
region in the minor groove of DNA, controlling gene transcription by changing DNA folding 
and recruiting other transcription-related factors (Watanabe et al., 2013; reviewed in Wang, Y. 
et al., 2019). 
Notably, c-Jun has also been found to directly bind to MDM2 (mouse double minute 2 
homolog) promoter to regulate MDM2 expression in colorectal cancer (Wang, B. et al., 2015). 
MDM2 has been identified to repress transcriptional activity of tumor suppressor p53. Wang 
et al. (2015) further showed that in colorectal cancer decreased miR-194 (microRNA-194) 
expression resulted in MAP4K4 (MAP kinase kinase kinase kinase 4) activation, which in turn 
led to activation of JNK and c-Jun. Similarly, also decreased miR200c has been reported to 
lead to activation of JNK2 and c-Jun in colorectal cancer, resulting in enhanced P-gp- (P-
glycoprotein) mediated invasion and metastasis (Sui et al., 2014). In addition, TGF-β is known 
to promote p38α-dependent phosphorylation of c-Jun at Ser63, which leads to c-Jun activation 
and binding to the promoter of Snail1. Snail1 expression then induces migration and invasion 
in prostate cancer (Thakur et al., 2014). Gao et al. (2014), in turn, showed that c-Jun directly 
activates FUT1 (alpha 1, 2-fucosyltransferase 1) transcription by binding its promoter in 




several tumor-promoting abilities, including cell proliferation, invasion, metastasis, and drug 
resistance (Gao, N. et al., 2014).   
2.2 OTHER AP-1 PROTEINS  
 
2.2.1 JunB and JunD 
The Jun proteins share many structural and biochemical properties, but differ in their biological 
functions. All jun genes are intronless (www.ensembl.org). JunB, as well as c-Jun, contains a 
JNK-docking site, but JunB does not have a typical JNK phosphorylation site in its 
transactivation domain, and thus, JNK cannot activate it in the same manner as c-Jun (Jin, J. 
Y. et al., 2011).  
The effect of JunB on neoplastic transformation is context-dependent such that JunB may 
function as a tumor suppressor or tumor promoter.  JunB can have both cell division-inhibiting 
and cell division-promoting activities depending on the cell cycle stage and the environmental 
conditions (reviewed in Piechaczyk and Farras, 2008). JunB has been found to be 
downregulated in human high-grade prostate cancer and to have tumor suppressor activity in 
the context of PTEN loss (Thomsen et al., 2015). On the other hand, JunB may have an 
important role in promoting cell invasion, migration, and distant metastasis in head and neck 
squamous cell carcinoma, and cell invasion and angiogenesis in von Hippel-Lindau defective 
renal cell carcinoma (Hyakusoku et al., 2016; Kanno et al., 2012). JUNB has been shown to 
activate Vegfa (Schmidt et al., 2007), which is the master regulator of angiogenesis (Olsson et 
al., 2006). 
JunB is often thought to be antagonistic to c-Jun. For example, dominant negative JunB mutant 
lacking the transactivating domain promotes epidermal malignancy, while the opposite is seen 
with the dominant negative mutant of c-Jun, TAM67 (Jin, J. Y. et al., 2011). Further, knocking 
down JunB by using a specific short hairpin RNA (shRNA) induces transcriptional expression 
of c-Jun in immortalized fibroblasts, leading to a significant increase in AP-1 activity (Gurzov 
et al., 2008). This may be due to negative regulation of c-Jun expression by JunB through 
competition for the AP-1 site within the c-jun promoter.  
The regulatory mechanisms of JunD, by contrast, are different from the other AP-1 proteins. 
JunD is not regulated as an immediate early gene, but its mRNA is detectable in quiescent cells 




Hernandez et al., 2008). In addition, JunD suppresses Ras-mediated transformation, whereas 
c-Jun cooperates with Ras to transform cells (Pfarr et al., 1994). In prostate cancer, JunD plays 
an important role in cell proliferation, and failure of JunD protein degradation may induce 
resistance to the proliferation inhibitory effects of TGF- at advanced stages of cancer (Millena 
et al., 2016).  Unlike c-Jun and JunB, JunD does not undergo ubiquitination-mediated 
proteasomal degradation or modification by the small ubiquitin-related modifier (SUMO) 
family proteins (reviewed in Piechaczyk and Farras, 2008; Hernandez et al., 2008).  
2.2.2 Fos family 
The Fos family of transcription factors includes c-Fos, FosB, Fra-1, Fra-2, and smaller FosB 
splice variants FosB2 and deltaFosB2 (reviewed in Milde-Langosch, 2005). Fos family 
members are not able to form homodimers, but they dimerize with Jun family members to form 
the AP-1 transcription factor complex. Like other AP-1 proteins, Fos family members have a 
bZIP for dimerization and DNA-binding, but only c-Fos and FosB proteins have a C-terminal 
transactivation domain. MAP kinases ERK1 and ERK2 phosphorylate c-Fos at Ser374 
(reviewed in Roskoski, 2012). The functional domains and phosphorylation sites of c-Fos are 
shown in Figure 4. It was initially proposed that Fra-1, Fra-2, and FosB2 have an inhibitory 
function on AP-1 activity (reviewed in Tulchinsky, 2000). However, subsequent results have 
shown that although Fra1 and Fra2 lack the potent transactivation domains, they might be 
involved in the progression of many tumor types and have a positive effect on tumor invasion 
(Milde-Langosch et al., 2008; Milde-Langosch et al., 2004 reviewed in Milde-Langosch, 
2005). 
 




In addition to c-Jun, c-Fos is a main AP-1 protein in mammalian cells. It was first identified as 
the viral oncoprotein v-Fos in the Finkel-Biskis-Jinkins murine osteogenic sarcoma virus (FBJ-
MSV) (Curran et al., 1983). Furthermore, c-Fos was found to be transforming in rat fibroblasts 
(Miller et al., 1984). Like c-Jun, c-Fos is an unstable protein that can be rapidly induced by 
mitogenic stimuli (Greenberg and Ziff, 1984). It is targeted for ubiquitination and degradation 
by lysine-specific demethylase 2B (KDM2B)-containing E3 ligase and can be stabilized by 
EGF-promoted phosphorylation, which dissociates c-Fos from its ubiquitin E3-ligase (Han et 
al., 2016). c-Fos overexpression in mice can cause osteosarcoma formation (Wang, Z. Q. et al., 
1995). c-Fos is also frequently found to be overexpressed in human cancers such as cervical 
and thyroid cancers and oral squamous cell carcinoma (Cheung et al., 1997; Kataki et al., 2003; 
Dong et al., 2014). 
2.2.3 ATF/CREB family 
ATF1, ATF2, LRF1/ATF3, ATF4/CREB2, ATF5/ATFx, ATF6, B-ATF, JDP1, and JDP2 
belong to the ATF/CREB family of bZIP transcription factors. They bind to the 8-base 
palindromic CRE promoters that respond to elevated cAMP. In addition, ATF2 binds to other 
elements, such as the AP-1 element, the proximal element of the IFN- promoter, the stress-
response element of the ho-1 gene, and the UV-response element (reviewed in Vlahopoulos et 
al., 2008). The ATF/CREB family of transcription factors shares the ability to respond to 
environmental signals and maintains cellular homeostasis (Hai and Hartman, 2001). ATF2 
regulates transcriptional responses associated with cell proliferation and differentiation, 
tumorigenesis, and apoptosis. JNK and p38 phosphorylate ATF2, as well as c-Jun, in response 
to cellular stress, which, in turn, enables the heterodimer formation. Indeed, c-Jun-ATF2 is a 
common dimer in oncogenic processes (reviewed in Vlahopoulos et al., 2008). ATF2 has been 
found to play a role in several cancers such as prostate and breast cancer, leukemia, 
neuroblastoma, and melanoma (reviewed in Vlahopoulos et al., 2008). In addition, many other 
ATF/CREB family members are also positively associated with cancer progression, e.g. ATF1 
with human melanoma cells (reviewed in Leslie and Bar-Eli, 2005) and thyroid papillary 
carcinoma (Ghoneim et al., 2007), CREB with human lung cancer cell lines (Linnerth et al., 
2005), and ATF6 with hepatocarcinogenesis (Arai et al., 2006).    
JDP2 interacts with c-Jun, but also with the transcription factors ATF2 (Jin, C. et al., 2001) and 
CCAAT/enhancer-binding protein gamma (reviewed in Tsai et al., 2016). JDP2 can bind both 
TPA- and cAMP-response elements, resulting in the inhibition of transcription. JDP2 acts as a 




decrease of c-Jun expression and an increase of JunB, JunD, and Fra2 expression (Heinrich et 
al., 2004). In addition, Heinrich et al. (2004) found JDP2 to be able to inhibit Ras-driven 
transformation of NIH 3T3 cells. JDP2 is widely expressed in normal mammalian tissues, and 
its activity is regulated by phosphorylation and SUMOylation (Wang, C. M. et al., 2017). 
2.2.4 MAF family  
The Maf transcription factors are members of the bZIP transcription factors belonging to the 
AP-1 superfamily. Mafs can be divided into two Maf families: so-called large Mafs, which 
include c-Maf, MafA, MafB, and NRL proteins (reviewed in Eychene et al., 2008), and small 
Mafs, including MafF, MafK, and MafG, which lack the N-terminal activation domain 
(reviewed in Katsuoka and Yamamoto, 2016; Kannan et al., 2012). Large Mafs are oncogenes 
and their transforming activity relies on overexpression (reviewed in Eychene et al., 2008). c-
maf is the cellular homolog of v-maf, which is the transforming gene of the avian retrovirus 
AS42. v-maf was first isolated from spontaneous musculo-aponeurotic fibrosarcoma in 
chicken, and it can transform primary chicken embryo fibroblasts (CEFs) (Nishizawa et al., 
1989). Overexpressed c-Maf has been found, for example, in half of the multiple myelomas, 
where it upregulates cyclin D2, CCR1 (leading to tumor survival and expansion), and integrin 
7 (leading to increased tumor-stroma interactions). c-Maf can form homodimers or 
heterodimers with other bZIP transcription factors. c-Maf and MafA can form stable 
heterodimers with Jun and bind -TGC TGA C TCA GCA- DNA motif, which also contains an 
internal Jun:Fos site. Another palindromic DNA sequence where Maf preferentially binds is –
TGC TGA CG TCA GCA-, and both of these sequences are Maf recognition elements 
(MAREs) (Kataoka et al., 1994). 
3. POLYAMINES AND THEIR BIOSYNTHETIC ENZYMES 
3.1 POLYAMINES AND THEIR FUNCTIONAL ROLES IN CELLS 
Polyamines (putrescine, spermidine, and spermine) are small, organic polycations that have 
positive charges distributed along a conformationally flexible carbon chain (Figure 5).  Thus, 
they interact with negatively charged macromolecules such as DNA, RNA, acidic proteins, and 
acidic phospholipids. Further, through their aliphatic hydrocarbon backbones polyamines are 
able to establish hydrophobic interactions as well. Polyamines have thus the capability to 
interact simultaneously with different macromolecular structures at the same time (reviewed in 
Sanchez-Jimenez et al., 2019). By binding to cellular macromolecules, polyamines have an 




ionic balance (reviewed in Igarashi and Kashiwagi, 2019). In addition, they regulate many 
essential cellular functions such as gene expression, cell proliferation, and apoptosis. Further, 
polyamines play an important role in signaling processes, including the regulation of both the 
expression and activation state of MAP kinases (reviewed in Ramani et al., 2014).  
 
 
Figure 5. Structure of polyamines. 
Eukaryotic cells need polyamines for normal cell proliferation and development (reviewed in 
Tabor and Tabor, 1984; Cohen, 1998). In normal physiological conditions, intracellular 
polyamine concentration is tightly controlled and dysregulation of the polyamine biosynthetic 
pathway leads to different pathological conditions, including neurodegenerative diseases, 
digestive diseases, and cancer (reviewed in Park, M. H. and Igarashi, 2013; Nowotarski et al., 
2013; Sanchez-Jimenez et al., 2019). Indeed, elevated levels of polyamines have been 
associated with several human cancers such as breast, colon, and skin cancers (Manni et al., 
1995; Gilmour, 2007; Upp et al., 1988). Most of the hallmarks of cancer described by Hanahan 
and Weinberg (2011) are affected by polyamines, e.g. they improve the ability of cancer cells 
to invade and metastasize, but also decrease the antitumor immune functions of immune cells 
(reviewed in Sanchez-Jimenez et al., 2019). 
3.2 BIOSYNTHETIC ENZYMES OF POLYAMINES 
The two main regulatory enzymes of polyamine biosynthesis are ODC and AdoMetDC 
(reviewed in Miller-Fleming et al., 2015). Figure 6 shows a simplified diagram of the locations 








Figure 6. Simplified diagram of polyamine biosynthesis. The enzymes are indicated in 
boldface in ovals. AdoMetDC: S-adenosylmethionine decarboxylase; ODC: ornithine 
decarboxylase; SPDS: spermidine synthase; SPMS: spermine synthase. 
 
3.2.1 Ornithine decarboxylase (ODC) 
The first and rate-limiting step in polyamine biosynthesis is catalyzed by ODC, 
decarboxylating L-ornithine into putrescine, the first polyamine. ODC is a ubiquitously 
expressed enzyme, which is found in all types of cells. It is controlled in many ways, including 
transcriptional and translational regulation and protein turnover. The transcriptional control 
occurs in response of the Odc gene promoter region to hormones, growth factors, tumor 
promoters, and oncoproteins such as MYC and RAS (Hölttä et al., 1988; reviewed in Pegg, 
2006). Indeed, Odc is a well-known target of the c-MYC oncoprotein, which increases the 
activity of the MYC/MAX transcription complex that binds to the Odc promoter (Pena et al., 
1993; Pena et al., 1995; Tobias et al., 1995; Bello-Fernandez et al., 1993). In quiescent cells, 
the MYC antagonist MNT/MAX complex occupies this site (Nilsson and Cleveland, 2004). At 
the translational level, one interesting example of the negative translational control of ODC is 





The degradation rate of ODC is also tightly regulated, and the half-life of ODC is very short 
(Russell and Snyder, 1969). In response to intracellular polyamine levels, ODC degradation  is 
controlled by an autoregulatory loop involving specific polypeptides acting as ODC inhibitors 
called antizymes (Az) (reviewed in Hayashi et al., 1996; Kahana, 2009; Coffino, 2001) and 
their counteractors called  antizyme inhibitors (AzI) (reviewed in Kahana, 2009; Kahana, 2018; 
Ramos-Molina et al., 2018). In mammalian cells, there are three well-characterized 
homologous antizymes Az1, Az2, and Az3, and one putative member termed Az4, and two 
antizyme inhibitors AzI1 and AzI2. In its active state, ODC is a loosely bound homodimer that 
easily dissociates into monomers. Az binds non-covalently to ODC subunits with higher 
affinity than the ODC subunits to each other, inactivating ODC and targeting it to ubiquitin-
independent degradation by proteasome 26S (reviewed in Pegg, 2006; Ramani et al., 2014; 
Kahana, 2018). AzI is highly homologous to ODC, but lacks ornithine-decarboxylating 
activity. It can bind with higher affinity to Az than Az binds to ODC, rescuing ODC from the 
interaction with Az and degradation (reviewed in Kahana, 2018).   
Previously, ODC has been shown to induce transformation of immortalized rodent fibroblasts, 
and further induce tumors in nude mice (Auvinen et al., 1992; Auvinen et al., 1997). Because 
ODC and polyamine levels have been found to be highly elevated in proliferating tumor cells, 
inhibition of ODC is speculated to be a good way to combat cancer (reviewed in Shantz and 
Levin, 2007). 
3.2.2 S-adenosylmethionine decarboxylase (AdoMetDC) 
AdoMetDC catalyzes the decarboxylation of S-adenosylmethionine, which acts as an 
aminopropyl donor in the biosynthesis of spermidine and spermine. AdoMetDC is another key 
enzyme in the biosynthesis of polyamines, regulating the formation of the higher polyamines 
spermidine and spermine. It is also highly regulated, in the same way as ODC (Suzuki et al., 
1993; Shantz et al., 1992; reviewed in Pegg et al., 1998; Pegg, 2009). The cellular need for 
polyamines determines the amount and activation of the AdoMetDC protein. Interestingly, 
increased putrescine content increases the activation of AdoMetDC, while increased 
spermidine and spermine content decreases the transcription of AdoMetDC gene (probably 
through a polyamine-responsive element) and the translation of AdoMetDC mRNA [through 
ORFs (open reading frames) in the 5’-UTR (untranslated region) of the mRNA] (reviewed in 
Pegg, 2009). Similarly to ODC, AdoMetDC has a fast turnover rate via degradation by the 26S 





AIMS OF THE STUDY 
 
The aim of this thesis was to examine the role of transcription factor c-Jun in transformation 
of different cell types. c-Jun is constitutively activated in many transformed cell lines and 
human cancers, including ODC-transformed mouse fibroblasts and human melanoma cells 
arising from various genetic alterations.  
Specific aims were as follows: 
 To examine the potential transforming activity of AdoMetDC, the other key regulatory 
enzyme of polyamine biosynthesis, in addition to ODC. 
 To evaluate the significance of c-Jun phosphorylation and activation for ODC-, 
AdoMetDC-, and Ha-ras-induced cell transformation of mouse fibroblasts. 
 To identify potential transformation-relevant genes regulated by c-Jun in ODC-, 
AdoMetDC-, and RAS-transformed mouse fibroblasts and human melanoma cells, and 








MATERIALS AND METHODS  
4. CELL CULTURE (I-IV) 
Mouse fibroblast cell lines used in the study are presented in Table 2 and human cells in Table 
3. All cells were cultured at 37ºC in a 5% CO2 atmosphere.  
 
Table 2. Mouse cell lines. 
Name Parental cell line Vector and insert Publication 
NIH3T3 - - II 
4N NIH3T3 pLTRpoly I, III 
Amdc NIH3T3 pLTRpoly and AdoMetDC sense I, III 
Amdc-as* NIH3T3 pLTRpoly and AdoMetDC antisense I 
N1 NIH3T3 pSV2neo II, IV 
Odc NIH3T3 pLTRpoly and human ODC cDNA II, IV 
Odc-n** Odc - II, IV 
E4 NIH3T3 pGEJ6.6 (c-Ha-rasval12) II, IV 
NIH3T3-pLRT-TAM67§ NIH3T3 pLRT-TAM67 II 
Amdc-pLRT-TAM67§ Amdc pLRT-TAM67 III 













Amdc-pLRT-LOX§ Amdc pLRT-human LOX - 
Odc-pLRT-LOX§ Odc pLRT-human LOX IV 
*Spermidine was used at a low concentration (1 M) in Amdc-as cell cultures to prevent the counter-selection of 
cells expressing adequate levels of AdoMetDC antisense-mRNA to block the synthesis of essential polyamines. 
**Odc-n cells are derived from the Odc cell line-induced tumors of nude mice. 
§Doxycycline (1 g/ml) was used in the growth medium to induce TAM67 or LOX expression. 
 
The NIH3T3 cell line was from the American Type Culture Collection. Normal mouse 
fibroblast cell lines (NIH3T3, 4N, and N1) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen) supplemented with 2 mM L-glutamine, 100 units/ml penicillin 
and 100 g/ml streptomycin, and 5% newborn calf serum (NBCS; Life Technologies, Inc.). 
Transformed mouse fibroblast cell lines (Amdc, Amdc-as, Odc, Odc-n and E4) were cultured 
as the normal fibroblast cell lines, except that 5% fetal bovine serum (FBS; Bioclear) was used 
instead of NBCS.  
 
Transformed fibroblast cell lines were stably transfected with a tetracycline-inducible 
expression system of the transactivation domain deletion mutant of c-Jun (pLRT-TAM67) or 




pLRT-TAM67. These cell lines (Amdc-/ Amdc-as-/ Odc-/ Odc-n-/ E4-pLRT-TAM67/LOX) 
were cultured in MEM (Invitrogen), supplemented with 2 mM L-glutamine, 50 g/ml 
gentamicin, and Tet system-approved fetal bovine serum (Tet-FBS; Clontech). NIH3T3-
pLRT-TAM67 cells were cultured with NBCS. 
Table 3. Human cells. 
Name Description Publication 
HT-1080 Fibrosarcoma cell line III 
42V Primary melanocytes IV 
Mela3 Primary melanocytes IV 
Mela TN45 Primary melanocytes IV 
EL29 Primary melanoma cells IV 
WM115 Primary melanoma cell line (vertical growth phase) IV 
WM793 Primary melanoma cell line (vertical growth phase) IV 
WM239 Metastatic melanoma cell line (lymph node metastasis) IV 
MM170 Metastatic melanoma cell line (lymph node metastasis) IV 
SK-MEL-28 Metastatic melanoma cell line (skin metastasis) IV 
BLM Metastatic melanoma cell line (lung metastasis) IV 
SK-MEL-103 Metastatic melanoma cell line IV 
SK-MEL-147 Metastatic melanoma cell line IV 
HMVEC Microvascular endothelial cells IV 
HES Primary embryonic skin fibroblasts IV 
Fibroblast Primary foreskin fibroblasts IV 
Fibroblast Primary adult skin fibroblasts IV 
 
For a detailed description of human cells, culture conditions, and references see Study IV (for 
HT-1080 see Study III). Primary human melanocytes 42V, Mela3, and Mela TN45 were grown 
as previously described (Alanko et al., 1999; Kääriäinen et al., 2006; Soikkeli et al., 2010). 
Human fibrosarcoma cell line HT-1080 and metastatic melanoma cell lines SK-MEL-103, SK-
MEL-147, and BLM were grown in DMEM containing 10% FBS and antibiotics. Human 
primary embryonic skin fibroblasts (HES), melanoma cells isolated from a primary tumor 
(EL29), melanoma cells isolated from a primary melanoma of vertical growth phase (WM115 
and WM793), and cells from a metastatic melanoma (WM239, MM170, and SKMel-28) were 
cultured in RPMI 1640 containing 10% FBS and antibiotics. Human microvascular endothelial 
cells (HMVECs) were grown in growth factor-supplemented medium 131 (Gibco/Invitrogen). 
5. PATIENT SAMPLES (IV) 
Benign nevi and primary cutaneous melanomas were obtained by surgical excision at Helsinki 




taking the specimens were approved by the Ethics Committees of Helsinki University Central 
Hospital. 
6. RNA ANALYSES 
6.1 MICROARRAY ANALYSIS (III, IV) 
Polyadenylated RNAs were extracted from the exponentially growing Amdc-pLRT-TAM67, 
Amdc-as-pLRT-TAM67, and Odc-pLRT-TAM67 cells by oligo(dT) cellulose affinity 
chromatography (Roche Diagnostics). TAM67 expression was induced (+dox) or not (-dox) 3 
and 6 days before RNA extraction by 1 g/ml doxycycline. Polyadenylated RNAs were 
reverse-transcribed with Cy3 and Cy5 end-labeled random 9-mers to generate fluorescent 
single-stranded cDNA probes. These were then competitively hybridized to and analyzed with 
Mouse GEM2/Unigene1 cDNA LifeArrays (Incyte Genomics) containing 9596 expressed 
elements representing 9307 unique genes or clusters. 
Total RNAs were extracted with RNeasy Kit (Qiagen) from Amdc-pLRT-TAM67 and Odc-
pLRT-TAM67 cells induced (+dox) or not (-dox) with 1 g/ml doxycycline for 3 or 5 days, 
and from N1, Odc, and E4 cells at 2-3 days after plating in the serum containing media. 
Biotinylated cRNA targets were produced from the RNAs and hybridized to Affymetrix 
oligonucleotide MOE430 set arrays containing more than 30,000 gene probes. 
6.2 NORTHERN BLOT ANALYSIS (I, IV) 
The AdoMetDC mRNA levels of the normal 4N fibroblast, Amdc, and Amdc-as cells, and the 
LOX mRNA levels of the Odc-pLRT-LOX clones 2 and 6 were confirmed by Northern blot 
analysis. LOX expression was induced (+dox) or not (-dox) with 1 g/ml doxycycline for 3 
days in the Odc-pLRT-LOX clones. Polyadenylated RNA samples were resolved in agarose 
gels and transferred to Hybond-N nylon membrane (Amersham Pharmacia Biotech). 
[32P]dCTP-labeled AdoMetDC and LOX antisense cDNA probes were hybridized to 
membranes. [32P]dCTP-labeled -actin cDNA was used as a control and hybridized to check 
the -actin expression levels. Hybridization signals were detected and quantified by using 





6.3 REVERSE TRANSCRIPTION-PCR (RT-PCR) ANALYSIS (III, IV) 
The expression levels of the identified, c-Jun regulatable, candidate genes (Itg6, Itg7, and 
Lox) in the transformed fibroblast cell lines and the genes related to these molecules (Itg1, 
Itg4, Loxl1, Loxl2, Loxl3, and Loxl4) were confirmed by reverse transcription (RT)-PCR 
analysis. In addition, the expression levels of LOX, LOXL1, LOXL2, LOXL3, and LOXL4 in 
melanoma cells were analyzed by RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) was used as a control with mouse cells and -actin (ACTB) with human cells. The 
mouse- and human-specific primers and PCR conditions used are shown in Tables 4 and 5, 
respectively. 
 
 Table 4. Mouse-specific PCR primer sequences and PCR conditions used in Studies III and 
IV. 
































































Table 5. Human-specific PCR primer sequences and PCR conditions used in Study IV. 































*The number of cycles was optimized to be in the linear range. F=forward, R=reverse. 
7. PROTEIN ANALYSES 
7.1 WESTERN BLOTTING (I-IV) 
Whole-cell lysates, secreted proteins from concentrated serum-free conditioned media, and 
immunoprecipitated proteins in 1x Laemmli sample buffer were resolved by SDS-PAGE and 
transferred onto nitrocellulose membranes. The membranes were probed with primary 
antibodies (Table 6) and horseradish peroxidase conjugated secondary antibodies. Blots from 













Table 6. Antibodies used in Studies I-IV. 
Target Clone/Code Source Application* Manufacturer** Publication 
Actin (Ab-1) JLA20 mouse WB Merck II, III 
















p-c-Jun 9164 rabbit IHC CST III 
p-c-Jun (Ser63)  rabbit WB NEB I 
Erk1/Erk2  mouse WB Zymed  I 
Flag-Tag M2 mouse WB Sigma-Aldrich II 





























































JNK1 (FL) F-3 mouse WB Santa Cruz I 
JNK1/JNK3 C-17 rabbit IP Santa Cruz I 
Lysyl oxidase L4669 rabbit WB Sigma-Aldrich IV 
Lysyl oxidase-like 2 ab96233 rabbit WB Abcam IV 
Lysyl oxidase 
propeptide 
NB110-41568 rabbit WB Novus Biologicals IV 
MKK4/SEK1/JNKK1 M7433 rabbit WB Sigma-Aldrich I, II 
p38 C-20 rabbit WB Santa Cruz II 
P-p38 
(Thr180/Tyr182) 
 rabbit WB Cell signalling 
Technology 
II 
-tubulin 600-401-880 rabbit WB Rockland III 
*WB=Western blot, IHC=immunohistochemistry, IF=immunofluorescent stain, IP=immunoprecipitation, 
FC=flow cytometry, FB=function blocking, **CJT=Cell Signaling Technology, NEB=New England Biolabs, Inc, 
BM=Boehringer Mannheim.   




7.2 IMMUNOFLUORESCENT STAINING (III) 
Amdc cells were grown on glass coverslips, which were then fixed with 3.5% 
paraformaldehyde and permeabilized with 0.1% Triton X-100. In the stainings, anti-integrin 
6 or 7 primary antibodies and FITC-conjugated goat anti-rat secondary antibody were used. 
7.3 IMMUNOPRECIPITATION ANALYSIS (III) 
To determine the binding partners of integrin 6, Amdc cells were lysed and 1.5 mg proteins 
were incubated with integrin 6 antibody (MA6 or GoH3) overnight at 4°C. 
Immunocomplexes were collected using anti-rat IgG agarose (Sigma), washed, and eluted. The 
candidate binding partners integrin 1 and 4 were then analyzed by Western blotting.  
7.4 IMMUNOHISTOCHEMISTRY (III) 
Paraffin-embedded human tissue samples of low- and high-grade fibrosarcomas, and normal 
esophagus and bronchus as a control, were used in immunohistochemical staining of integrin 
6. In addition, c-Jun and phospho-c-Jun (Ser73) were analyzed by immunohistochemical 
analyses in different grade human sarcomas.  
7.5 FLOW CYTOMETRY (III) 
The flow cytometer (FACScan; Becton Dickinson) was used to analyze the cell surface levels 
of integrin 6 in 4N and Amdc cells. The cell suspensions were first incubated with anti-
integrin 6 antibody or isotype control antibody, washed, and incubated with secondary 
biotinylated goat anti-rat antibody, and finally with r-phycoerythrin-streptavidin (Vector 
Laboratories, Inc.).  
8. FUNCTIONAL ANALYSES 
8.1 TRANSFECTION EXPERIMENTS (I-IV) 
8.1.1 Plasmids (I, II) 
Plasmids used in the study are summarized in Table 7. To investigate the effect of 
overexpression of AdoMetDC, pLTRpoly vector with human AdoMetDC cDNA in sense or 
antisense orientations together with neo selection marker were transfected into normal NIH 
3T3 mouse fibroblast cells and Rat1 fibroblasts using LipofectAMINE. Stable cell lines were 




with empty pLTRpoly vector and pSV2neo), Amdc (AdoMetDC-pLTRpoly and pSV2neo), 
and Amdc-as (AdoMetDC-as-pLTRpoly and pSV2neo). 
Table 7. Plasmids. 
Plasmid Description Manufacturer/ Provider/ 
Reference 
Publication 











decarboxylase in antisense 
orientation 
 I 
pSV2neo neomycin selection marker  I 
pcDNA3 empty vector Invitrogen I, II 
DN JNK1 FLAG-JNK1 (APF), dominant 
negative JNK1 
Roger J. Davis, James R. 
Woodgett (Derijard et al., 1994) 
I, II 
DN SEK1 SEK1 (AL), dominant negative 
SEK1/MKK4 
Roger J. Davis, James R. 
Woodgett (Yan et al., 1994) 
I, II 
DN MKK4 Flag-MKK4 (Ala), dominant 
negative MKK4 
(Whitmarsh et al., 1997) II 
pMT 108 c-Jun (Treier et al., 1995; Papavassiliou 
et al., 1995) 
II 
pMT 111 c-JunS63,73A (Treier et al., 1995; Papavassiliou 
et al., 1995) 
II 
pMT 161 c-JunS63,73A,T91,93A (Treier et al., 1995; Papavassiliou 
et al., 1995) 
II 
pCMV empty vector (Brown et al., 1993) I 
pCMV-TAM67 deletion mutant of c-Jun (Brown et al., 1993) I, II 
pBabe puro puromycin selection marker (Morgenstern and Land, 1990) I,II 
pLRT-TAM67 inducible deletion mutant of c-Jun   II, III, IV 
pLRT-LOX inducible lysyl oxidase  IV 
pLRT empty inducible vector (Watsuji et al., 1997) IV 
 
To examine the significance of JNK activation in the transformed Amdc, Odc, and E4 cells, 
empty pcDNA3 vector or dominant negative mutants of JNK1 or SEK1/MKK4 were 
transfected into the cells together with a pBabe puro selection marker, using LipofectAMINE 
Plus (Life Technologies). The cells were selected for resistance to puromycin, and pools of 




To examine the role of c-Jun phosphorylation and activation in Odc and E4 cells, plasmids 
with normal c-Jun (pMT 108) as a control, phosphorylation site mutants of c-Jun (pMT 111 
and pMT 161), and transactivation domain deletion mutant of c-Jun (pCMV-TAM67) were 
transfected together with a pBabe puro selection marker. In addition, empty pCMV vector and 
pCMV TAM67 together with a pBabe puro were transfected into Amdc and Amdc-as cells. 
8.1.2 Tetracycline-inducible expression system (II-IV) 
Tetracycline-inducible expression system of TAM67 and LOX were generated by inserting 
these cDNAs into reverse tetracycline-regulated retroviral vector pLRT (Watsuji et al., 1997). 
The pLRT-TAM67 plasmid was transfected into the normal NIH 3T3 mouse fibroblasts, Odc, 
Odc-n, E4, and Amdc cells, and the pLRT-LOX plasmid into the Odc and Odc-n cells using 
LipofectAMINE plus or LipofectAMINE 2000 (Invitrogen). Transfected cells were selected 
by Blasticidin (Invitrogen) and several clones were picked up. The cloned cells were tested for 
their inducibility of TAM67 or LOX expressions by 1 g/ml doxycycline (Sigma). The best 
clones for further investigation were selected by morphological analyses and immunoblotting 
(TAM67 expression), and Northern blotting, RT-PCR, and immunoblotting (LOX expression).       
8.1.3 siRNA and shRNA (III, IV) 
To knock down c-Jun expression in Amdc cells, small interfering RNA (siRNA) 
oligonucleotide pool to c-Jun (Santa Cruz Biotechnology) and c-Jun short hairpin RNA 
(shRNA) construct (kindly provided by Dr. Kazushi Inoue, Wake Forest University Health 
Sciences, Winston-Salem, NC) were used. siRNA-A was used as a control for the former and 
an empty pSuper.retro.puro vector for the latter. Transfections were performed using 
OligofectAMINE (siRNAs), LipofectAMINE 2000 (Invitrogen), and Fugene 6 (shRNAs) 
(Roche Diagnostics) reagents. 
To knock down the expression of LOX or LOXL2 in WM793 and SK-MEL-147 melanoma 
cells, MISSION® shRNA Lentiviral particles were used (Sigma-Aldrich). The clone 
TRCN0000045991 (SHCLNV-NM_002317) targeting LOX, clones TRCN0000046195 and 
TRCN0000046197 targeting LOXL2 (SHCLNV-NM_002318), and MISSION® Non-




8.2 ACTIVITY ASSAYS (I-III) 
8.2.1 AdoMetDC and ODC assays (I, II) 
AdoMetDC and ODC activities were assayed by measuring the release of 14CO2 from S-
adenosyl-L-(carboxyl 14C) methionine or L-(1-14CO2) ornithine, respectively, as previously 
described (Hölttä et al., 1988). 
8.2.2 MAPK assay (I) 
The activity of MAPK was assayed after its immunoprecipitation from 1 mg of soluble proteins 
with a polyclonal MAPK R2 antibody, and using ATP, (-32P)ATP, and MAPK substrate 
peptide (APRTPGGRR) (Paasinen-Sohns and Hölttä, 1997). 
8.2.3 JNK assay (I) 
JNK activity was studied by using anti-JNK1 antibody and c-Jun(1-169)-GST fusion protein 
as a substrate (Paasinen-Sohns and Hölttä, 1997). On the solid phase kinase assay (Hibi et al., 
1993), the JNKs were purified by their binding to agarose-conjugated substrate GST-c-Jun. For 
the kinase reaction, ATP and (-32P)ATP were added and the phosphorylation of GST-c-Jun 
was analyzed by gel electrophoresis and quantification by autoradiography.  
8.2.4 Cathepsin L assay (III) 
The activity of cathepsin L was assayed as previously reported (Ravanko et al., 2004), in the 
presence of heparin. The possible interrelationship between integrin 6 and cathepsin L was 
evaluated by utilizing a neutralizing integrin 6 antibody. The effect of the antibody on 
cathepsin L activity was tested by incubating it with Amdc cells prior to and during culture 
both on plastic plates and on BD Biocoat Thin Layer Matrigel dishes. The growth medium was 
filtered to get rid of the antibody, and the secreted proteins were then concentrated and assayed 
for cathepsin L activity. 
8.2.5 Adhesion assay (III) 
The ability of Amdc cells to adhere on laminin- or fibronectin-coated plates was analyzed in 
the presence or absence of neutralizing antibodies to integrin subunits 6, 1, and 7 and 
isotype control antibody. The cells were pre-incubated (or not) with the neutralizing antibodies 
for 30 min and then allowed to adhere on laminin or fibronectin surfaces for another 30 min at 
37°C. The cells were then washed, trypsinized, and counted with Coulter particle counter 




8.2.6 Analysis of cell growth (II-IV) 
The effects of TAM67 or LOX expression on the growth of Odc-pLRT-TAM67, E4-pLRT-
TAM67, and NIH3T3-pLRT-TAM67, or Odc-pLRT-LOX cells, respectively, were evaluated. 
The cells were grown in the absence or presence of 1 g/ml doxycycline, and counted at 24-h 
intervals over 4 days (TAM67) or after 3 and 5 days (LOX) with a Coulter particle counter 
(Beckman Coulter). To determine the significance of integrin subunits 6, 1, and 7 in the 
proliferation of Amdc cells, function-blocking antibodies of these integrins or isotype control 
antibody (Table 6) were incubated with the cells 30 min before plating and during growth. The 
cells were then counted after 3 and 6 days with a Coulter particle counter.    
8.2.7 JNK inhibitors in cell culture (II) 
The effects of two different cell-permeable JNK inhibitors, L-stereoisomer of JNK peptide 
inhibitor 1 (L-JNK inhibitor 1) and JNK inhibitor II (Table 8), were investigated in Odc cells. 
Peptide inhibitor and its control (L-TAT) were added daily to the cultures. DMSO (0.1%) was 
used as a control for JNK inhibitor II. 
 Table 8. Inhibitors and control used in Studies I-IV. 
Inhibitor/ control Target Concentration Manufacturer Publication 
L-stereoisomer of JNK peptide 
inhibitor 1 (L-JNK inhibitor 1) 
JNK1, JNK2 1-25 M Alexis 
Biochemicals 
II 
L-stereoisomer of TAT control 
peptide (L-TAT) 
- 1-25 M Alexis 
Biochemicals 
II 
JNK inhibitor II (SP600125) JNK1, JNK2, JNK3 0.1-10 M Calbiochem II 
LOX inhibitor -
aminopropionitrile (APN) 
LOX family 250/500 M Sigma-Aldrich IV 
 
8.2.8 Soft agar growth assay (I, II) 
The ability of different cells, 4N as control, Amdc, Amdc-as (with 1 M spermidine), Amdc 
cells transfected with pCMV-TAM67, and Odc-pLRT-TAM67 cells with inducible TAM67, 
to grow anchorage independently in the soft agar was evaluated. TAM67 expression was 
induced or not with 1 g/ml doxycycline. For the assay, the cells in the growth medium with 
serum were mixed with agar (Difco) to yield a 0.35% agar mixture, which was then overlaid 
on 0.7% bottom agar and covered with growth medium. The colony formation was followed 
for 2-4 weeks, replenishing the growth medium twice a week.      
8.2.9 Matrigel invasion assay (II-IV) 
The ability of Odc-pLRT-TAM67, E4-pLRT-TAM67, Amdc-pLRT-TAM67, and Odc-pLRT-




doxycycline was examined by using 3D growth factor-reduced Matrigel (BD Biosciences). 
Further, the effect of lysyl oxidase inhibitor -aminopropionitrile (APN) (see Table 8) on 
invasion of melanoma cell lines WM793 and SK-MEL-147 cultured with or without human 
primary embryonic skin fibroblasts (HES) was evaluated. For these co-cultures, the HES and 
melanoma cells WM793 and SK-MEL-147 were labeled with Celltracker Green CMFDA or 
Celltracker Red CMTPX (Life Technologies), respectively. In addition, the effect of APN to 
Odc-pLRT-LOX cells grown in Matrigel with or without doxycycline was examined.  In these 
assays, doxycycline and BAPN were added to both the matrix and medium. Cells were allowed 
to grow in Matrigel for 1-5 days before photographing. 
To also analyze the effect of Itg6, 1, or 7 on cell invasion, neutralizing antibodies to these 
integrins or isotype control antibodies were preincubated with Amdc cells and human HT-1080 
fibrosarcoma cells for 30 min before the invasion assays in Matrigel. The antibodies were also 
added to both the matrix and medium.   
8.2.10 Tumorigenicity assay (I, II) 
In the tumorigenicity assay, 4N (control), Amdc, Amdc-as, and Amdc-as cells with spermidine 
or Odc-pLRT-TAM67 cells were inoculated subcutaneously into both flanks of nude mice. The 
tumor formation of 4N, Amdc, Amdc-as, and Amdc-as with spermidine was followed by 
caliper measurements two to three times a week until reaching ethical limits (with Amdc and 
Amdc-as cells reached in 10 days). The tumor growth of the normal 4N cells was followed for 
up to 62 days. The mice inoculated with Odc-pLRT-TAM67 cells received (or not) 1 M 
doxycycline in their drinking solution for TAM67 induction. These mice were sacrificed after 





RESULTS AND DISCUSSION 
9. C-JUN IS RELEVANT FOR CELL TRANSFORMATION INDUCED BY 
ADOMETDC (I), ODC, AND HA-RAS (II) 
9.1 ADOMETDC-, ODC-, AND HA-RAS-TRANSFORMED CELLS 
In this study, we investigated whether, in addition to ODC, also the other key regulatory 
enzyme of polyamine biosynthesis, AdoMetDC, is involved in cell transformation. To this end, 
we transfected AdoMetDC cDNA in sense and antisense orientations into NIH3T3 fibroblasts 
and Rat1 cells. Overexpression of AdoMetDC was also found to transform these rodent 
fibroblasts and induce highly invasive tumors in nude mice. AdoMetDc activity was 30- to 40-
fold higher in AdoMetDC-transfomed cells than in parental cells. Surprisingly, in addition to 
AdoMetDC, also the expression of AdoMetDC cDNA in the antisense orientation and with 1 
M spermidine in the culture medium led to cell transformation. Notably, these latter cells had 
similar polyamine biosynthetic enzyme and polyamine patterns to those of the ODC-
transformed cells, with an enhanced ODC activity and an elevated putrescine content. The 
increase in ODC activity in the AdoMetDC antisense cells is probably a compensatory 
mechanism. These transformed cells were also able to induce highly invasive tumors in nude 
mice. 
In subsequent studies of the molecular mechanisms of transformation, we used NIH3T3 mouse 
fibroblast cell lines transformed by AdoMetDC, ODC, and c-Ha-rasVal12 (Amdc, Odc, and E4 
cells, respectively). In our previous studies, we had obtained evidence that the proto-oncogene 
c-Jun is constitutively active in Odc cells (Hölttä et al., 1998). Furthermore, c-Jun had been 
shown to become transcriptionally activated by the phosphorylation of Ser63 and Ser73 in Ras-
transformed cells and to be required for transformation (Johnson, R. et al., 1996). Ras proto-
oncogenes (K-, Ha-, and N-ras) are small GTPase proteins that relay signals from the outside 
of the cell into the cell’s nucleus. Certain missense point mutations, particularly those in codons 
12 and 61 (such as amino acid valine replacing amino acid glycine in codon 12), obliterate 
GTPase activity and lead to constitutively active Ras protein, found in many cancers. Here, we 




9.2 EFFECTS OF JNK INHIBITORS AND DOMINANT NEGATIVE MUTANTS OF SEK1/MKK4 AND 
JNK1 ON CELL TRANSFORMATION 
JNK and ERK pathways are usually involved in c-Jun activation. We had previously found a 
constitutive activation of JNK and phosphorylation of c-Jun at serines 63 and 73 in ODC-
transformed cells (Hölttä et al., 1998). Here, we examined the significance of JNK activation 
in ODC-, AdoMetDC-, and RAS-transformed cells by using two different inhibitors of JNK, 
L-JNK inhibitor 1 (Dickens et al., 1997) and JNK inhibitor II (SP600125) (Bennett et al., 
2001;reviewed in Koch et al., 2015) as well as dominant negative mutants of JNK1 and its 
upstream activator MKK4. L-JNK inhibitor 1 blocks the activities of JNK1 and JNK2, and 
JNK inhibitor II blocks the activities of all three JNKs. Both of these inhibitors were able to 
reverse the morphology of Odc cells, but only partially. When using dominant negative mutants 
of SEK1/MKK4 in Odc and Amdc cells, the transformed morphology was also partially 
reversed. The same was seen after using dominant negative mutant of JNK1 in both cell lines. 
This shows that the MKK4/JNK pathway is involved in ODC- and AdoMetDC- induced 
transformations, but may not be the only one. We did not find ERK or p38 pathways to be 
activated (data not shown), but other pathways may be involved. DN SEK1 and DN JNK1 had 
no effect in Amdc-as cells supplemented with spermidine.  
9.3 EFFECTS OF DOMINANT NEGATIVE MUTANTS OF C-JUN ON CELL TRANSFORMATION 
To examine the significance of c-Jun phosphorylation and activation in ODC- and ras- induced 
transformations, we used two phosphodeficient mutants of c-jun: c-JunS63,73A and c-
JunS63,73A,T91,93A, and TAM67. In TAM67, most of the transactivation domain (amino acids 3-
122) of c-Jun is deleted (Brown et al., 1993). Schematic maps of these dominant negative 





Figure 7. Schematic structures of c-Jun and different dominant negative mutants of c-Jun.  
 
TAM67 can inhibit AP-1 activity through at least two mechanisms: blocking and quenching 
(Brown et al., 1996; Brown et al., 1994). In blocking, TAM67 homodimer binds DNA, 
blocking the response element, and in quenching, TAM67 heterodimer binds DNA but does 
not activate transcription. TAM67 was transfected to AdoMetDC sense- and antisense-induced 
transformed cell lines Amdc and Amdc-as. Previously, TAM67 has been used to investigate 
the role of AP-1 in other cell types as well (Li, J. J. et al., 2000; Liu, Y. et al., 2002).  We found 
phosphorylation of c-Jun to be important for the transformed phenotype of Amdc, Odc, and E4 
cells, but TAM67 had the greatest effect on the morphology, reversing the transformed 
phenotype of all cells completely. We further generated cell lines carrying a tetracycline-
inducible expression system of the TAM67 (pLRT-TAM67). Figure 8 presents a diagram of 
the reverse tet-regulated retroviral vector construct, where the expression of TAM67 can be 
induced by doxycycline. After transfection of the cells with the construct, numerous cell clones 
with altered morphology were isolated and the expression levels of TAM67 (without or with 
doxycycline induction) analyzed by Western blotting. The best clones with a minimal leakage 
and strong TAM67 expression after induction were then selected for further studies. TAM67 
expression was also found to downregulate the endogenous c-Jun expression, likely due to its 
binding to a variant c-Jun response element in the promoter region of the c-Jun gene itself. 
Most interestingly, the transformed morphology of the cells could be reversibly regulated by 




cells was reversed to a normal flattened phenotype within 1-3 days, and after removal of 
doxycycline the cells again returned to the transformed state. 
   
Figure 8. Schematic model of the reverse tet-regulated retroviral vector, where the expression 
of TAM67 can be induced by doxycycline (modified from (Watsuji et al., 1997). The addition 
of doxycycline leads to binding of rtTA to tetO, which allows the activation of TAM67. 
Blasticidin is used in the selection of the cells with the vector.  
 
9.4 TAM67 INHIBITS COLONY FORMATION OF ADOMETDC- AND ODC-TRANSFORMED CELLS IN 
SOFT AGAR, THEIR INVASION IN 3D-MATRIGEL, AND PROLIFERATION IN VITRO 
In Amdc and Amdc-as+spd cells, the expression of TAM67 inhibited the growth of the cells in 
soft agar (I). The same was true for the ODC-transformed Odc-pLRT-TAM67 cells, after 
induction of TAM67 expression by doxycycline (II). TAM67 further effectively inhibited the 
invasion of ODC- and AdoMetDC-transformed cells as well as RAS-transformed E4 cells in 
3D-Matrigel (II, III). In addition, the inducible expression of TAM67 was found to inhibit the 
proliferation of ODC-, AdoMetDC-, and c-Ha-rasval12-transformed cells (II, and data not 
shown). The effects of TAM67 were confirmed not to be due to TAM67 interfering with the 
AdoMetDC or ODC activities.  
9.5 TAM67 INHIBITS TUMOR FORMATION IN NUDE MICE 
To test the tumorigenicity of the ODC-transformed cells in detail, Odc-pLRT-TAM67 cells 
were inoculated subcutaneously at both flanks of the nude mice. The mice with induced 




days, while the controls (uninduced cells) developed large tumors (II). In line with our study, 
TAM67 has also been shown to have antitumor effects in other mouse xenograft models of 
cancer such as those of colon cancer and non-small cell lung cancer (Suto et al., 2004; Shimizu 
et al., 2008). 
 
10. IDENTIFICATION OF C-JUN-REGULATED AND TRANSFORMATION-
ASSOCIATED GENES BY MICROARRAY ANALYSES (III, IV) 
We next examined the transformation-associated gene expression changes regulated by c-Jun 
in ODC- and AdoMetDC-transformed cells and inducible Odc-, Amdc-, and Amdc-as-pLRT-
TAM67 cell lines by Incyte Genomics cDNA and Affymetrix’s oligonucleotide microarrays 
(III, IV). Relatively few genes were found to be involved in the transformations by the cDNA 
arrays (see Tables 9-14), including upregulated cyclin D1, proliferin, high mobility group 
protein, prothymosin 4, integrin 7, and integrin 6, and downregulated cysteine-rich 61 
(CYR61),  fibrillin-1, fibulin-5, and lysyl oxidase. These genes were confirmed to be 
differentially expressed by Affymetrix’s microarray analyses (III, IV and (Nummela et al., 
2006). 
 
Table 9. Most downregulated genes in Odc-pLRT-TAM67 cells following TAM67 expression, 
as analyzed with Incyte Genomics Mouse UniGene1 cDNA LifeArrays.  
Genbank Gene Gene description Odc TAM67  
+dox vs. -dox* 
AI152562 Prl2c5 Prolactin family 2, subfamily c, member 5 -2.4 
AA066647 Lgals3 Lectin, galactose binding, soluble 3 -2.3 
AA067083 Hmga1-rs1 High mobility group AT-hook I, related sequence 1 -2.2 
AA870247 Prl2c2 Prolactin family 2, subfamily c, member 2 -2.1 
AA671769 Itgb7 Integrin beta 7 -2.0 
AI466833 Ngef Neuronal guanine nucleotide exchange factor -1.8 
AA185547 Kcnn4 Potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 4 
-1.8 
AI225491 Fosl1 Fos-like antigen 1 -1.8 
AA619763 Ctsl Cathepsin L -1.6 
AI120968 Sgk1 Serum/glucocorticoid regulated kinase 1 -1.5 
AA066601 Wfdc 15b WAP four-disulfide core domain 15B -1.5 
AA760223 Emp3 Epithelial membrane protein 3 -1.5 
W14224 Ndrg1 N-myc downstream regulated gene 1 -1.5 
AA088968 Itga6 Integrin alpha 6 -1.5 
AA117547 Ccnd1 Cyclin D1 -1.5 
*Expression changes of Odc-pLRT-TAM67 cells between cells with 1 g/ml doxycycline (+dox) and without 





Table 10. Most upregulated genes in Odc-pLRT-TAM67 cells following TAM67 expression, 
as analyzed with Incyte Genomics Mouse Unigene1 cDNA LifeArrays. 
Genbank Gene Gene description Odc TAM67 
+dox vs. –dox* 
AA437518 Fbln5 Fibulin-5 4.4 
AA273494 Vdr Vitamin D receptor 3.5 
AA221794 Rgs2 Regulation of G-protein signaling 2 3.1 
AA711852 Adamts1 A disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 1 
2.9 
AI020539 Slpi Secretory leukocyte peptidase inhibitor 2.8 
W11432 Amotl2 Angiomotin-like 2 2.7 
W83882 Lox Lysyl oxidase 2.5 
AA733629 C3 Complement component 3 2.4 
AA267178 Cyp1b1 Cytochrome P450, family 1, subfamily b, polypeptide 1 2.1 
AA037995 Mfap5 Microfibrillar associated protein 5 2.1 
*Expression changes of Odc-pLRT-TAM67 cells between cells with 1 g/ml doxycycline (+dox) and without 
doxycycline (-dox) after three days’ induction. The values are fold changes. 
 
Table 11. Most downregulated genes in Amdc-pLRT-TAM67 cells following TAM67 
expression, as analyzed with Incyte Genomics Mouse Unigene1 cDNA LifeArrays. 
Genbank Gene Gene description Amdc TAM67 




AI152562 Prl2c5 Prolactin family 2, subfamily c, member 
5 
-2.9 -5.1 
AI466833 Ngef Neuronal guanine nucleotide exchange 
factor 
-2.6 -6.6 
AA420078 Itgbl1 Integrin, beta-like 1 -2.4 -2.9 
AA067083 Hmga1-rs1 High mobility group AT-hook I, related 
sequence 1 
-2.4 -3.0 
AA124623 Evi2 Ecotropic viral integration site 2 -2.3 -4.0 
AA185547 Kcnn4 Potassium intermediate/small 
conductance calcium-activated channel, 
subfamily N, member 4 
-2.2 -3.9 
AA870247 Prl2c2 Prolactin family 2, subfamily c, member 
2 
-2.0 -4.3 
AA117547 Ccnd1 Cyclin D1 -2.0 -2.9 
AA667906 Csrp2 Cysteine and glycine-rich protein 2 -2.0 -3.4 
AA798948 Cav1 Caveolin 1, caveolae protein -1.9 -2.2 
AA671769 Itgb7 Integrin beta 7 -1.9 -3.7 
W09641 Tmsb4x Thymosin, beta 4, X chromosome -1.8 -3.1 
AA619763 Ctsl Cathepsin L -1.7 -2.7 
AA088968 Itga6 Integrin alpha 6 -1.5 -2.8 
Expression changes of Amdc-pLRT-TAM67 cells between cells with 1 g/ml doxycycline (+dox) and without 








Table 12 Most upregulated genes in Amdc-pLRT-TAM67 cells following TAM67 expression, 
as analyzed with Incyte Genomics Mouse Unigene1 cDNA LifeArrays. 
Genbank Gene Gene description Amdc TAM67 
+dox vs. -dox* 
Amdc TAM67 
+dox vs. –dox**   
AA510298 Plau Plasminogen activator, urokinase 3.2 3.7 
W12942 Tnc Tenascin C 3.2 3.2 
AA437518 Fbln5 Fibulin-5 2.9 4.6 
W16059 Gsto1 Glutatione S-transferase omega 1 2.8 <1.5 
AW210317 Fbn1 Fibrillin 1 2.7 4.1 
AA209882 Nr4a1 Nuclear receptor subfamily 4, group A, 
member 1 
2.6 2.1 
AI020539 Slpi Secretory leukocyte peptidase inhibitor 2.5 3 
AA466852 Cyr61 Cysteine rich protein 61 2.4 4.7 
AI155437 Akr1c18 Aldo-keto reductase family 1, member 
C18 
2.4 5 
AI892243 Fth1 Ferritin heavy chain 1 2.4 2.4 
AA562569 Npc2 Niemann Pick type C2 2.3 2 
AA656268 Pde4b Phosphodiesterase 4B, cAMP-specific 2.3 2.3 
AA510727 Pla2g4a Phospholipase A2, group IVA 2.2 1.6 
AA547214 Irf9 Interferon regulatory factor 9 2.1 1.6 
AA250679 Akr1c12 Aldo-keto reductase family 1, member 
C12 
2.1 3.1 
W88093 Mgp Matrix gamma-carboxyglutamate (gla) 
protein 
2.1 3.3 
AA855996 Bgn Biglycan 2.1 2.5 
AI447967 Maml2 Mastermind like 2 (Drosophila) 2.1 <1.5 




AI019469 Glul Glutamate-ammonia ligase (glutamine 
synthetase) 
2.1 3.1 
W13004 Ptgis Prostaglandin I2 (prostacyclin) 
synthase 
2.1 2.2 
AA037995 Mfap5 Microfibrillar-associated protein 5 <1.5 2.3 
W83882 Lox Lysyl oxidase <1.5 2.1 
Expression changes of Amdc-pLRT-TAM67 cells between cells with 1 g/ml doxycycline (+dox) and without 
doxycycline (-dox) after *three days’ induction and after **six days’ induction. The values are fold changes. 
Table 13. Most downregulated genes in Amdc-as-pLRT-TAM67 cells following TAM67 
expression, as analyzed with Incyte Genomics Mouse Unigene1 cDNA LifeArrays. 
Genbank Gene Gene description Amdc-as TAM67 
+dox vs. –dox* 
AA067083 Hmga1-rs1 High mobility group AT-hook I, related sequence 1 -2.7 
AA771678 Prkg2 Protein kinase, cGMP-dependent, type II -2.5 
AI152562 Prl2c5 Prolactin family 2, subfamily c, member 5 -2.4 
AI466833 Ngef Neuronal guanine nucleotide exchange factor -2.3 
W15804 Igfbp6 Insulin-like growth factor binding protein 6 -2.2 
AI120968 Sgk1 Serum/glucocorticoid regulated kinase 1 -2.2 
AA185547 Kcnn4 Potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 4 
-2.1 
AI225491 Fosl1 Fos-like antigen 1 -2.0 
AA671769 Itgb7 Integrin beta 7 -2.0 
*Expression changes of Amdc-as-pLRT-TAM67 cells between cells with 1 g/ml doxycycline (+dox) and without 




Table 14. Most upregulated genes in Amdc-as-pLRT-TAM67 cells when TAM67 expression 
is induced by doxycycline, as analyzed with Incyte Genomics Mouse Unigene1 cDNA 
LifeArrays. 
Genbank Gene Gene description Amdc-as TAM67 
+dox vs. –dox* 
AA711852 Adamts1 A disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif 1 
3.9 
AA037995 Mfap5 Microfibrillar-associated protein 5 3.5 
AA755007 Dcn Decorin 3.4 
AA733629 C3 Complement component 3 3.3 
AI047160 Ptn Pleiotrophin 2.8 
AA437518 Fbln5 Fibulin-5 2.8 
AI019567 Tlr1 Toll-like receptor 1 2.7 
AA444232 Akap12 A kinase (PRKA) anchor protein (gravin) 12 2.6 
AA796641 Clec3b C-type lectin domain family 3, member 3 2.6 
AI893922 Ptx3 Pentaxin-related gene 2.5 
W71229 Adamts2 A disintegrin-like and metallopeptidase (reprolysin 
type) with thrombosponding type 1 motif 2 
2.4 
AI604159 Fzd1 Frizzled homolog 1 (Drosophila) 2.3 
AA543149 II6st Interleukin 6 signal transducer 2.2 
AA874687 Fyn Fyn proto-oncogene 2.2 
AA221794 Rgs2 Regulator of G-protein signaling 2 2.1 
AA518187 Ogn Osteoglycin 2.1 
AA475186 Irs1 Insulin receptor substrate 1 2.0 
W53231 Cd82 CD82 antigen 2.0 
AA671168 Anxa6 Annexin A6 2.0 
AI020539 Slpi Secretory leukocyte peptidase inhibitor 2.0 
W83882 Lox Lysyl oxidase 1.5 
*Expression changes of Amdc-as-pLRT-TAM67 cells between cells with 1 g/ml doxycycline (+dox) and without 
doxycycline (-dox) after three days’ induction. The values are fold changes. 
 
Previously, the cell cycle protein cyclin D1 has been reported to be a target gene of c-Jun. 
Cyclin D1 functions as a regulator of CDK4 and CDK6 kinases, whose activity is required for 
cell cycle G1/S transition. Hennigan and Stambrook (2001) found that a high level of TAM67 
expression inactivates the cyclin D1:CDK4/6 complex and thus arrests fibrosarcoma cells in 
G1.  Proliferin (also known as mitogen-regulated protein) is involved in angiogenesis (Toft et 
al., 2001) and AP-1 has been found to be the mediator of serum-dependent proliferin expression 
in mouse fibroblasts (Groskopf and Linzer, 1994). Hommura et al. (2004), in turn, have 
reported that high mobility group protein AT-hook 1 (HMGA1 or HMG-I/Y) is a direct 
transcriptional target of c-Jun and is necessary for c-Jun-induced anchorage-independent 
growth in Rat1a cells. Dhar et al. (2004) showed HMGA1 to be a TAM67 target gene and 
related to transformation. HMGA1 binds to the minor groove of chromosomal DNA and 




to be a possible determinant of invasiveness and metastasis (Liau et al., 2006). In addition, we 
have previously reported the actin sequestering protein thymosin 4 to be upregulated in Amdc 
cells and to be regulated by c-Jun (Nummela et al., 2006). This regulation was, however, 
probably indirect because the decrease in thymosin 4 mRNA following TAM67 induction 
was a relatively slow process. The genes found to be downregulated in transformed cells and 
upregulated after TAM67 induction were mostly extracellular matrix proteins. For example, 
CYR61 (CCN1) is a secreted matricellular protein that is a mediator of collagen homeostasis 
and known to be regulated by AP-1 (Quan et al., 2010). FBLN5 is an integrin-binding 
extracellular matrix protein that is important for embryonic development and organogenesis 
(Noda et al., 2015). It acts as an elastogenic organizer by depositing on microfibrils, promoting 
aggregation of tropoelastin molecules through coacervation, and interacting with the elastin 
crosslinking enzymes LOXL1, 2, and 4 (Hirai et al., 2007). Indeed, microfibrils, such as 
fibrillin 1, act as scaffolds in the morphogenesis of elastic fibers. FBLN5 is further a 
multifunctional signaling molecule, which, in addition to its structural function, mediates cell-
cell and cell-matrix communication (Albig and Schiemann, 2005). FBLN5 is known to 
stimulate MAPKs that enhance AP-1 activity stimulated by TGF-. In tumorigenesis, FBLN5 
is mainly a tumor suppressor through its control of cell proliferation, motility, and angiogenic 
sprouting (Albig and Schiemann, 2005). Surprisingly, it has also been shown that FBLN5 
stimulates DNA synthesis and motility in fibroblasts and fibrosarcoma cells (Schiemann et al., 
2002). In our study, FBLN5 was downregulated in transformed cells in a c-Jun regulatable 
manner. However, when Odc and Amdc cells were compared with their normal counterparts, 
no difference was detected in FBLN5 expression. Previous findings suggest that the 
downregulated expression of FBLN5 may enable cancer formation and progression, as it 
functions as a tumor suppressor by inhibiting migration and invasion of ovarian cancer cells 
(Heo et al., 2015), cell proliferation and invasion of gliomas (Sheng et al., 2015) and metastasis 
of lung cancer (Chen et al., 2015). Microfibrillar-associated protein 5 (MFAP5) is also a 
multifunctional protein playing a role in cell signaling during microfibril assembly (Lemaire et 
al., 2007), elastinogenesis, and cell survival. However, its expression has mainly been reported 
to increase in human cancers (Leung et al., 2014).  
Of the detected gene expression changes, we further examined integrins 6 and 7 because 
they were found to be both upregulated in transformed cells compared with parental cells and 




additional studies since it was both downregulated in transformed cells compared with normal 
cells and upregulated in transformed cells after TAM67 induction. 
11. FUNCTIONAL CHARACTERIZATION OF C-JUN-REGULATED AND 
TRANSFORMATION-ASSOCIATED GENES 
11.1 INTEGRINS IN MOUSE FIBROSARCOMA CELLS (III) 
Integrins are a family of cell surface transmembrane glycoproteins that function primarily as 
receptors for ECM ligands, including secreted ECM proteins fibronectin, laminin, and 
collagen. Integrins are composed of non-covalently associated  and  subunits forming 
heterodimers with a large extracellular domain that binds ECM molecules and a short 
cytoplasmic tail (an exception is the 4 subunit) that links ECM to the actin cytoskeleton 
(reviewed in Hynes, 2002; Luo et al., 2007; Springer and Wang, 2004; Kadry and Calderwood, 
2020). Altogether 18  and 8  subunits exist that combine into at least 24 different 
heterodimers (reviewed in Takada et al., 2007) exhibiting overlapping but non-redundant 
functions (reviewed in Hynes, 2002; Luo et al., 2007). Integrins mediate interactions between 
cells and their extracellular microenvironment. In the “inside-out” signaling, integrin activation 
is triggered by a cytoplasmic signal or changes in the cytoskeleton, which lead to the 
modulation of integrin affinity for extracellular ligands. In addition to ECM components as 
ligands, some integrins bind to counter-receptors on other cells. The “outside-in” signaling, in 
turn, activates a number of signaling pathways that are important in the regulation of survival, 
proliferation, gene transcription, differentiation, migration, and apoptosis (reviewed in Hynes, 
2002; Luo et al., 2007; Takada et al., 2007; Bianconi et al., 2016). Integrins can further regulate 
cell shape and stress fiber formation by activating kinases that phosphorylate cytoskeletal 
proteins (reviewed in Romero et al., 2020; Bianconi et al., 2016).  
When the extracellular environment of the cancer cell changes, for example, upon its 
proteolytical degradation or stiffening, integrins sense these changes and trigger a range of 
cellular responses, but also play a crucial role in promoting a more malignant cancer cell 
phenotype. Indeed, integrins have an important role in different steps of cancer progression, 
including uncontrolled and limitless proliferation, cell survival and evasion of apoptosis, 
detachment, intravasation into lymphatic and blood vessels, migration and invasion of tumor 
cells, metastasis, and promotion of tumor angiogenesis (reviewed in Sun et al., 2014; Seguin 
et al., 2015; Ganguly et al., 2013; Huttenlocher and Horwitz, 2011; Garmy-Susini and Varner, 




11.1.1 Integrins 6 and 7 are upregulated in AdoMetDC-transformed fibroblasts in a c-Jun- 
regulatable manner 
Integrins 6 and 7 were found to be overexpressed in Amdc cells and downregulated in 
normalized Amdc-pLRT-TAM67 cells after TAM67 induction. Thus, these gene expression 
changes were both c-Jun- and transformation-dependent. As integrin 7 is thought to be 
leukocyte-specific, its overexpression in fibrosarcoma cells is an interesting finding. 
Previously, integrin 7 has been identified as a target gene of the oncogene c-MAF, which 
belongs to the AP-1 family of transcription factors (Hurt et al., 2004). The overexpression of 
integrins 6 and 7 was verified at the RNA level by RT-PCR and at the protein level by 
immunofluorescent staining of 4N and Amdc cells, and Amdc-pLRT-TAM67 cells with and 
without doxycycline. The expression of integrin 6 at protein level was additionally confirmed 
with FACS analysis and Western blotting.  
Integrin 7 overexpression has also been detected in multiple myeloma cells, where it mediates 
regulation of adhesion, migration, and invasion (Neri et al., 2011) and in different lymphomas, 
including mantle cell lymphoma, thymic lymphoma, and mucosa-associated T- and B-cell non-
Hodgkin lymphomas (Morito et al., 2006). Notably, the integrin 7 inducer c-MAF is 
overexpressed in nearly 50% of multiple myeloma patients (Hurt et al., 2004). Integrin 6, in 
turn, has been found to be overexpressed in esophageal squamous cell carcinomas and in 
hepatocellular carcinoma cells, where it was suggested to promote proliferation, invasion, and 
metastasis of the cells (Kwon et al., 2013; Ma et al., 2017; Lv et al., 2013). 
11.1.2 Integrin 1 is a dimerization partner of integrin 6 in Amdc cells 
The integrin subunit 6 can form heterodimers with integrin subunits 1 or 4, the ligand of 
both integrins 61 and 64 being laminin. The main dimerization partner of integrin 6 in 
Amdc cells was explored by immunoprecipitation analysis utilizing two different Itg6 
antibodies. The captured proteins in the Itg6 immunoprecipitates were immunoblotted with 
antibodies specific to 1 and 4. In addition, the expression levels of these integrin subunits 
were analyzed by RT-PCR and Affymetrix microarrays. In these analyses, integrin 4 subunit 
was not found to be complexed with 6 subunit at all or only minimally, whereas 61 was 
detected as the major heterodimer expressed in Amdc cells. Integrin 1 is a more universal 
integrin subunit than 4, with most cells in the body expressing it. In addition, it can form 
altogether 11 different integrin heterodimers in all four receptor groups [laminin, RGD 




in (Barczyk et al., 2010)]. Integrin subunit 4, in turn, can form a heterodimer only with 6. 
Nevertheless, integrin 64 has been found to be upregulated in many tumor types, being also 
a potential target for cancer therapy (reviewed in Giancotti, 2007). 
Integrin subunit 7 heterodimerizes with integrin subunits 4 and E. The ligands of 47 are 
fibronectin, vascular cell adhesion molecule 1 (VCAM-1), and mucosal vascular addressin cell 
adhesion molecule 1 (MAdCAM-1), which are present on the surface of endothelial cells, bone 
marrow stromal cells, and epithelial cells. On the other hand, E7 retains intraepithelial 
lymphocytes within the gut epithelium by binding E-cadherin (Neri et al., 2011). However, we 
were unable to clarify the main dimerization partner of Itg7 in Amdc cells by 
immunoprecipitation. Yet, our initial results by RT-PCR showed that Amdc cells express 
ItgE. It remains to be elucidated which of the integrins, 47 or E7, is present in 
fibrosarcoma cells.  
11.1.3 Integrin 61 is involved in adhesion of Amdc cells to laminin 
Because integrin 61 is a laminin receptor, we used function-blocking antibodies against 
integrin 6 and its partner, integrin 1, with Amdc cells and tested their ability to inhibit 
binding to laminin and Matrigel, which consists mostly of laminin. The function-blocking 
antibody of integrin subunit 6 considerably inhibited the adhesion to laminin, and the integrin 
subunit 1 antibody inhibited the binding completely, probably because integrin 1 subunit 
has numerous dimerization partners. However, the function-blocking antibody of integrin 
subunit 7 did not inhibit Amdc cells from binding to fibronectin, the ligand of integrin 47. 
11.1.4 Integrin 61 is involved in invasion 
As Amdc cells are highly invasive, we further examined whether the upregulation of integrin 
6 is necessary for invasion. In these assays, we utilized again function-blocking integrin 6 
antibodies (as well as neutralizing antibodies for its partner Itg1) and 3D Matrigel matrix. 
Indeed, both function-blocking integrin 6 and integrin 1 antibody fully inhibited invasion. 
Notably, in addition to the Amdc cells, also human HT-1080 fibrosarcoma cells were found to 
rely on integrin 61 to be able to invade. Integrin 7 antibody, in turn, had no effect on 
invasion. The functional significance of integrin 7 in transformation remains to be clarified 




11.1.5 Integrin 6 is found in invasion fronts of human high-grade fibrosarcomas 
The potential clinical significance of integrin 6 in human fibrosarcomas and other soft-tissue 
sarcomas was then studied by immunohistochemistry. Interestingly, strong staining of Itg6 
was detected in the invasion fronts of high-grade tumors. Moreover, integrin 6 
immunoreactivity was correlated with the expression of activated c-Jun. 
11.2  LYSYL OXIDASE FAMILY PROTEINS IN FIBROSARCOMA AND MELANOMA CELLS (IV) 
The lysyl oxidase family consists of lysyl oxidase (LOX) and lysyl oxidase-like 1-4 (LOXL1, 
LOXL2, LOXL3, and LOXL4) proteins. They are copper-dependent amine oxidases 
containing differing N-terminal regions and a conserved C-terminal domain (reviewed in 
Finney et al., 2014). The structures of LOX family proteins are shown in Figure 9. The C-
terminal region contains a copper-binding motif for the protein conformation and a lysyl-
tyrosyl-quinone (LTQ) cofactor for the amine oxidase activity needed in crosslinking of 
collagen and elastin (reviewed in Nishioka et al., 2012). The N-terminal domains are more 
divergent, conferring individual functions (Molnar et al., 2003): LOX and LOXL1 contain 
prosequences enabling their secretion as inactive proenzymes and directing them to interact 
with the ECM. LOXL2, LOXL3, and LOXL4, in turn, contain four scavenger receptor 
cysteine-rich domains, which are thought to be involved in cell adhesion and protein-protein 
interactions.  
 
Figure 9. Structure of lysyl oxidase (LOX) and the other lysyl oxidase family members, lysyl 
oxidase-like 1-4 (LOXL 1-4). Modified from reviews of Finney et al. (2014), Nishioka et al. 





LOX is synthesized and secreted as a 50 kDa glycosylated proenzyme (Pro-LOX), which is 
cleaved extracellularly by bone morphogenetic protein 1 (BMP-1) and related proteases 
(tolloid-like 1 and 2) to the functional 32 kDa enzyme (LOX) and an 18 kDa propeptide (LOX-
PP) (Uzel et al., 2001). The activation of LOX is dependent on its binding to the fibronectin 
matrix (Fogelgren et al., 2005) and periostin, which binds both to BMP-1 and fibronectin 
(Maruhashi et al., 2010). LOX plays an essential role in the crosslinking of collagen and elastin 
in the ECM (Kagan and Li, 2003). In addition to having a role in connective tissue homeostasis, 
LOX is involved in the regulation of various cellular processes, such as cell adhesion, invasion, 
and migration, and also cell polarity and epithelial-mesenchymal transition in hypoxic 
conditions (El-Haibi et al., 2012; Kasashima et al., 2015; reviewed in Csiszar, 2001; Molnar et 
al., 2003). Further, it has been reported to have functions in the cytoplasm (Jansen and Csiszar, 
2007) and nucleus (Li, W. et al., 1997; Nellaiappan et al., 2000), where it may regulate 
transcription (Okkelman et al., 2014). 
LOX is essential for normal development, and the failure of LOX function can lead to several 
diseases (Tsuda et al., 2003). Indeed, deficient activity of LOX is related to many connective 
tissue disorders such as Ehler-Danlos syndrome, Menke’s syndrome, and cutis laxa 
(Kuivaniemi et al., 1985; Khakoo et al., 1997). Elevated LOX activity, in turn, is associated 
with various fibrotic diseases, including atherosclerosis, scleroderma, and liver cirrhosis 
(Kagan et al., 1981; Chanoki et al., 1995; Murawaki et al., 1991). Most interestingly, aberrant 
expression of LOX is found in many cancer cells, and paradoxically, LOX has been found to 
function as both a tumor promotor (Lee, Y. S. et al., 2017) and a tumor suppressor (reviewed 
in Siddikuzzaman et al., 2011). 
11.2.1 Lox is downregulated in ODC-transformed mouse fibroblasts in a c-Jun-dependent manner 
We found Lox to be downregulated in ODC-transformed Odc cells (both at the mRNA and 
protein levels) compared with normal N1 cells, and upregulated again in Odc-pLRT-TAM67 
cells upon reversal of transformation by TAM67 expression. 
11.2.2 Expression of Lox family members Lox-like1 and Lox-like3 is downregulated in Odc cells 
In addition to Lox, we examined the expression levels of the other Lox family members, Lox-
like 1-4, in Odc and parental N1 cells by Affymetrix microarrays and verified the results by 
RT-PCR. We found that, in addition to Lox, Loxl1 and Loxl3 were also downregulated in Odc 
cells when compared with N1 fibroblasts. Of these Lox family members, the highest expression 
levels were seen with Lox in the Odc cells. In contrast, Loxl4 was slightly upregulated in Odc 




11.2.3 Expression levels of Lox family members are downregulated in RAS-transformed fibroblasts 
Initially, LOX was identified as a “ras recision gene” (rrg) due to its ability to revert RAS-
mediated transformation of NIH 3T3 fibroblasts (Contente et al., 1990). Thereafter, rrg was 
identified as Lox and proposed to be a tumor suppressor (Contente et al., 1990; Kenyon et al., 
1991). Indeed, the expression of LOX has been shown to be decreased in various cells 
transformed by ras or ras-dependent oncogenes (Contente et al., 1990; Giampuzzi et al., 2001). 
Jeay et al. (2003) have further reported that the tumor suppressor action of LOX prevents the 
activation of NF-B in the ras-mediated transformation. 
In our study, we explored Lox in more detail and also Lox-like 1-4 in HRAS-oncogene-
transformed E4 cells. We found Lox expression to be extensively downregulated in E4 cells 
compared with normal N1 cells, but also the expression levels of Loxl1, Loxl3, and Loxl4 were 
slightly reduced, as analyzed by Affymetrix microarray and RT-PCR analyses. 
11.2.4 LOX family members are upregulated in melanoma cells 
Previously, Nummela et al. (2012) had observed alterations in the expression levels of LOX 
family members, especially an upregulation of LOXL2, in melanoma cell lines compared with 
normal melanocytes by microarray analyses. Similarly, an upregulation of c-Jun expression 
and activity had been detected in melanomas (Spangler et al., 2011); reviewed in (Kappelmann 
et al., 2014). Furthermore, at least the LOX gene has been shown to have an AP-1/c-Jun binding 
site in its promoter region (Hamalainen et al., 1993; Papachroni et al., 2010). Consequently, 
we were interested in extending our studies to the expression levels of all LOX family members 
in different melanoma cell lines. The gene expression levels of LOX and the LOX-like family 
members were evaluated at the mRNA level using microarray and RT-PCR analyses. Variable 
expression patterns were observed, depending on the melanoma cell line. However, the 
expressions of LOXL2 and LOXL3 were upregulated in nearly all of the melanoma cell lines 
examined. The expression levels of all lysyl oxidase family members in melanocytes and 
melanoma cells, as analyzed by RT-PCR, are shown in Table 15 (see also IV, Figure 4). LOX 
and particularly LOXL2 have been often found to be overexpressed in other human cancers as 









Table 15. Expression of LOX family members in human melanocytes and melanoma cells. 
 
Name Description LOX LOXL1 LOXL2 LOXL3 LOXL4 
42V Primary melanocytes - - - - - 
MELA3 Primary melanocytes - - - - - 
MELA-TN45 Primary melanocytes - - - - - 
EL29 Primary melanoma - - - x - 
WM115 Primary melanoma cell line (vgp) - - x x x 
WM793 Primary melanoma cell line (vgp) x - x x - 
WM239 Metastatic melanoma cell line (lnm) - - x x x 
MM170 Metastatic melanoma cell line (lnm) - - x x x 
SK-MEL-28 Metastatic melanoma cell line (sm) - - - x - 
BLM Metastatic melanoma cell line (lm) x x x - - 
SK-MEL-103 Metastatic melanoma cell line - - x x - 
SK-MEL-147 Metastatic melanoma cell line x x x x - 
vgp=vertical growth phase, lnm=lymph node metastasis, sm=skin metastasis, lm=lung metastasis 
x=upregulated expression 
 
Further, the protein expression levels of LOX and LOXL2 in human fibroblasts (HES) and 
three melanoma cell lines (SK-MEL-147, WM793, and WM239) were studied by Western blot 
analysis. The PRO-LOX protein level appeared to be high intracellularly, but it was found to 
be effectively processed to active LOX extracellularly in HES cells. In melanoma cells, the 
secreted protein levels of LOX were high only in WM793 cells, whereas the contents of 
LOXL2, both the cellular and secreted protein levels, were relatively high in all melanoma cell 
lines evaluated.  
We found the mRNA expression levels of LOXL1 and LOXL2 genes to be markedly 
upregulated in the primary melanoma tissue specimens compared with human benign nevi. 
Most interestingly, high LOXL2 expression appeared also to be associated with the formation 




11.2.5 LOX and LOX-like proteins are oppositely associated with invasion of ODC-transformed 
fibroblasts and melanoma cells  
We then examined the functional significance of LOX in ODC-transformed fibroblasts and 
melanoma cells. Paradoxically, LOX was found to be downregulated in mouse fibrosarcoma 
cells and upregulated in human melanoma cells. Similarly, LOX has been reported to be 
downregulated in human basal and squamous cell carcinomas, gastric cancers, and 
osteosarcoma tissues (Bouez et al., 2006; Kaneda et al., 2004; Xu, X. et al., 2013), but 
overexpressed in human esophageal squamous cell carcinoma, lung adenocarcinoma, and 
colorectal cancer (Baker et al., 2011; Sakai et al., 2009; Wilgus et al., 2010). Further, LOX has 
been known to be inactivated by methylation and loss of heterozygosity in human gastric 
cancers (Kaneda et al., 2004). 
To assess the role of LOX in Odc cells, we generated cell lines transfected with a tetracycline-
inducible expression system of pro-LOX (Odc-pLRT-LOX). The best clones, with low 
background expression in the absence of doxycycline, were selected for further studies. First, 
we examined the cell proliferation rates and found that the induced expression of pro-LOX 
markedly inhibited the growth of Odc-pLRT-LOX cells in 2D culture. Next, we used a 3D 
Matrigel assay to mimic the in vivo situation and found that induced expression of LOX led to 
an inhibition of the invasion of Odc-pLRT-LOX cells as well. When the cells were further 
incubated with the LOX inhibitor APN in the absence or presence of doxycycline, there was 
no effect on cell invasion. BAPN is known to bind irreversibly to the LOX active site, blocking 
its activity, and thus, preventing LOX from catalyzing the conversion of lysine residues to 
reactive aldehydes and the formation of crosslinks (Tang et al., 1983; Tang et al., 1989). The 
structural formula of BAPN is shown in Figure 10. Importantly, our results show that the 
enzyme activity of LOX had no effect on the invasion of Odc-pLRT-LOX cells. Previously, 
Palamakumbura et al. (2004) have found that lysyl oxidase propeptide (LOX-PP) inhibits Ras-
dependent cell transformation. Further, LOX-PP has been shown to inhibit the invasive 
phenotype and to function as a tumor suppressor in many transformed cell lines and cancers 
where the signals are mediated via RAS, e.g. in H1299 lung cancer and PANC-1 pancreatic 
cancer cell lines (Wu, M. et al., 2007) and epidermal growth factor receptor-2/neu-driven breast 
cancer cells (Min et al., 2007). Despite these findings, we did not observe any detectable 
increases in LOX-PP protein levels in the normal NIH3T3 compared with Odc cells or in Odc-
pLRT-LOX cells upon doxycycline-induced expression of LOX and inhibition of cell 
proliferation and invasion. Our studies thus suggest that the inactive pro-LOX (together with 







In addition to LOX, we investigated the significance of LOXL2 in melanoma cells. We tested 
the effects of BAPN on two melanoma cell lines, the primary melanoma cell line WM793 with 
low invasive capacity and the metastatic melanoma cell line SK-MEL-147 with high invasive 
activity, in 3D Matrigel. BAPN at a concentration of 500 M effectively inhibited the invasion 
of WM793 cells, but the invasion of SK-MEL-147 cells was only slightly or moderately 
reduced. Our group previously found that the invasion of melanoma cells is promoted and 
guided by fibroblasts (Yin et al., 2012). Indeed, when co-culturing melanoma cells and 
fibroblasts in 3D Matrigel the invasion was increased, and the BAPN treatment led to a 
complete inhibition of the co-invasive growth of fibroblasts and melanoma cells. Cancer-
associated fibroblasts (CAFs) have also been shown to play a crucial role in the promotion of 
cancer progression in many other cancer cells (Wen et al., 2019; Torres et al., 2015; Nguyen et 
al., 2019). 
Finally, we examined the consequences of knocking down LOX and LOXL2 proteins in 
WM793 cells by specific shRNAs. Notably, both the capability of the cells to proliferate in 2D 
culture and the capacity of the cells to invade in 3D Matrigel were markedly reduced. The 
depletion of LOXL2 almost completely blocked the invasive growth capacity of the cells, even 
more effectively than APN, suggesting that not only the activity but also the protein content 
of LOXL2 is important in the regulation of proliferation and invasion of these cells.   
 
Figure 10. Structural formula of 





 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
We first examined the significance of c-Jun phosphorylation and activation in AdoMetDC-, 
ODC-, and Ha-ras-transformed mouse fibroblast cell lines (Amdc, Odc, and E4 cells, 
respectively) by using dominant negative mutants of upstream kinases of the MAPK and JNK 
pathways, JNK inhibitors, phosphodeficient mutants of c-Jun, and transactivation domain 
deletion mutant of c-Jun (TAM67) and found them all to reverse the transformed phenotype to 
a variable extent. However, TAM67 was by far the most effective in reversing the transformed 
phenotype of these cells, indicating that phosphorylation is not the only way that c-Jun 
functions in transformation; other mechanisms are also involved. Further, we generated cell 
lines with a tetracycline-inducible expression system of TAM67. We were able to regulate the 
state of transformation and invasiveness of these cell lines, and, most importantly, also the 
tumorigenic activity of the cells in nude mice was blocked upon induction of TAM67 
expression.  
Next, these cell lines with inducible expression of TAM67 were used for screening the c-Jun-
regulated and potentially transformation-specific gene expression changes by DNA microarray 
analyses. We identified several interesting gene expression changes, including the upregulation 
of integrin 6 (Itg6) and integrin 7 (Itg7) and the downregulation of lysyl oxidase (Lox), 
in these fibrosarcoma cells. Functional analyses further revealed Itg6 and Lox to be intimately 
involved in the regulation of invasion of these cells. The expression of Itg6 was also found to 
be increased at the invasive edge of human high-grade fibrosarcomas. In the future, it will be 
interesting to examine the functional roles of c-Jun and integrin 6 in human fibrosarcomas in 
more detail. In addition, the behavior of the collagen and elastin crosslinking enzyme, LOX, 
as well as the other invasion-related proteins identified in the mouse fibrosarcoma cell lines, 
remains to be evaluated in human fibrosarcomas. Therapeutic strategies targeting these 
proteins, particularly the cell surface receptor integrin 61, may offer new means for treating 
aggressive fibrosarcomas.  
Recent evidence has shown a double-edged role for LOX in transformation, functioning as 
both a tumor suppressor and a tumor promoter. Indeed, we also found that, in contrast to 
fibrosarcoma cells, LOX was upregulated in human melanoma cells. As one explanation for 
this conundrum, we found that it is the inactive, unprocessed LOX (pro-LOX) that functions 




LOX that acts as a tumor promoter in human melanoma cells. In addition to LOX, we also 
observed LOXL2 to promote the proliferation and invasion of melanoma cells. It would be 
interesting to also investigate the functional significance of the other LOX-like family 
members, especially the often upregulated LOXL3, in melanoma cells. As LOXL2 was found 
to be upregulated in almost all melanoma cells evaluated and also in human melanomas, where 
high expression of LOXL2 was further associated with short survival of the patients, LOXL2 
provides an attractive potential target for therapy in human melanomas. Moreover, since our 
study showed the involvement of c-Jun in the regulation of many critical genes in the 
transformation of fibrosarcoma cells, it would be interesting to more closely examine the role 
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